C/EBPδ-induced epigenetic changes control the dynamic gene transcription of S100a8 and S100a9

Saskia-Larissa Jauch-Speer1, Marisol Herrera-Rivero2, Nadine Ludwig3, Bruna Caroline Véras De Carvalho1, Leonie Martens1,2, Jonas Wolf1, Achmet Imam Chasan1, Anika Witten2,4, Birgit Markus1, Bernhard Schieffer5, Thomas Vogl1, Jan Rossaint3, Monika Stoll2,6, Johannes Roth1*, Olesja Fehler1

1Institute of Immunology, University of Münster, Münster, Germany; 2Department of Genetic Epidemiology, Institute of Human Genetics, University of Münster, Münster, Germany; 3Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany; 4Core Facility Genomics, Medical Faculty Münster, University of Münster, Münster, Germany; 5Clinic for Cardiology, Angiology and Internal Intensive Medicine, University Hospital Marburg, Marburg, Germany; 6CARIM Cardiovascular Research School, Department of Biochemistry, Genetic Epidemiology and Statistical Genetics, Maastricht University, Maastricht, Netherlands

Abstract The proinflammatory alarmins S100A8 and S100A9 are among the most abundant proteins in neutrophils and monocytes but are completely silenced after differentiation to macrophages. The molecular mechanisms of the extraordinarily dynamic transcriptional regulation of S100a8 and S100a9 genes, however, are only barely understood. Using an unbiased genome-wide CRISPR/Cas9 knockout (KO)-based screening approach in immortalized murine monocytes, we identified the transcription factor C/EBPδ as a central regulator of S100a8 and S100a9 expression. We showed that S100A8/A9 expression and thereby neutrophil recruitment and cytokine release were decreased in C/EBPδ KO mice in a mouse model of acute lung inflammation. S100a8 and S100a9 expression was further controlled by the C/EBPδ antagonists ATF3 and FBXW7. We confirmed the clinical relevance of this regulatory network in subpopulations of human monocytes in a clinical cohort of cardiovascular patients. Moreover, we identified specific C/EBPδ-binding sites within S100a8 and S100a9 promoter regions, and demonstrated that C/EBPδ-dependent JMJD3-mediated demethylation of H3K27me3 is indispensable for their expression. Overall, our work uncovered C/EBPδ as a novel regulator of S100a8 and S100a9 expression. Therefore, C/EBPδ represents a promising target for modulation of inflammatory conditions that are characterized by S100a8 and S100a9 overexpression.

Editor's evaluation The study uses an elegant CRISPR/Cas9 screening approach in a myeloid cell line to identify the underlying regulators of the alarmins S100A8 and S100A9, which amplify inflammation. This approach identified the transcription factor C/EBP-δ as a regulator of S100A8 and S100A9 expression in the myeloid cell line and also showed a correlation between the expression levels of C/EBP-δ and the alarmins in patient samples of peripheral blood mononuclear cells. Furthermore, the authors also validate their findings in primary monocytes using mice with genetic C/EBP-δ deletion. This work will be of significant interest to researchers studying the regulation of immune responses and...
inflammation, and it also highlights how unbiased CRISPR/Cas9 screening can lead to novel mechanistic insights in myeloid cells.

Introduction

As the first line of immune defence, both monocytes and neutrophils are important for the modulation of the innate immune response. To amplify the immune response at sites of inflammation, the activation of further immune cells is required, mediated by the release of signaling molecules such as chemokines and DAMPs (damage-associated molecular patterns). The two members of the S100 family, S100A8 and S100A9, also termed myeloid-related proteins 8 and 14 (MRP8 and MRP14), respectively, belong to the group of DAMPs or so-called alarmins. Their primary expression is referred to myeloid lineage-derived cells, particularly neutrophils and monocytes, where S100A8 and S100A9 are predominantly present as a heterodimeric complex, also called calprotectin (Austermann et al., 2018).

Intracellularly, S100A8/A9 complexes represent up to 40% of the soluble protein content in neutrophils and about 5% in monocytes (Hessian et al., 1993). However, in mature macrophages, protein and mRNA expression of these factors is completely downregulated. This data indicates that expression of S100A8 and S100A9 is controlled by the most dynamic promoters in myeloid cells. The S100A8/A9 complex interacts with the cytoskeleton in a calcium-dependent manner. Calcium-induced (S100A8/A9)4 tetramer promotes tubulin polymerization and microtubule bundling, thereby affecting transendothelial migration of phagocytes (Leukert et al., 2006). During inflammation or tissue damage, S100A8/A9 is actively secreted by neutrophils and monocytes, and represents the most abundant DAMP/alarmin activating inflammatory processes in infection, cancer, autoimmunity, and cardiovascular diseases. The S100A8/A9 complex is recognized by Toll-like receptor 4 (TLR4), which leads to the production of proinflammatory cytokines and chemokines (Fassl et al., 2015). Accordingly, S100A9 knockout (KO) mice exhibit decreased pathogenic outcomes in several mouse models of disease, such as sepsis (Vogl et al., 2007), autoimmune disease (Loser et al., 2010) or arthritis (van Lent et al., 2008). In addition, S100A8 and S100A9 are highly abundant during infectious diseases and exhibit anti-microbial activities. The S100A8/A9 complex plays a crucial role in host defence against bacterial and fungal pathogens by sequestering manganese and zinc ions which compete with high affinity bacterial transporters to import these essential nutrient metals (Kehl-Fie and Skaar, 2010; Kehl-Fie et al., 2011). In contrast to the proinflammatory role of S100A8/A9, regulatory functions in terms of hyporesponsiveness in phagocytes, resembling a classical endotoxin-induced tolerance, have also been described (Freise et al., 2019).

In humans, S100A8/A9 is the most abundant alarmin in many clinically relevant diseases, and is closely associated with disease activity in rheumatoid arthritis (RA), inflammatory bowel disease, sepsis, cardiovascular diseases, multiple sclerosis, acute lung injury (ALI) and psoriasis (Foell et al., 2004). Altered S100A8/A9 expression has also been found in different cancer types, including gastric, colorectal, breast, lung, prostate and liver cancer (Cross et al., 2005). Despite the high expression in neutrophils and monocytes under inflammatory conditions, and the strong effects of S100A8 and S100A9 on disease activities, transcriptional mechanisms regulating these extreme dynamics of gene expression remain unclear. Identifying the mechanisms regulating S100a8 and S100a9 gene expression may open new insights into the pathological processes involving S100A8/A9 during inflammatory conditions.

So far, several potential transcription factors modulating S100a8 and S100a9 expression have been described (Kuruto-Niwa et al., 1998; Fujii et al., 2011; Lee et al., 2012; Liu et al., 2016; Yang et al., 2017), but their functional relevance remains unresolved. Many of the stated studies used malignant immortalized cell lines or even cell models whose homologous primary cells do not express these genes at all.

To overcome difficulties of artificial expression and malignant cell lines we used ER (estrogen-regulated) Hoxb8 cells, estrogen dependent transiently immortalized myeloid precursor cells that can be differentiated to primary monocytes and granulocytes upon estrogen-withdrawal (Wang et al., 2006a), and show the physiologically high dynamics of S100A8 and S100A9 mRNA and protein expression during differentiation. In order to detect genes involved in the regulation of S100a8 and S100a9 expression in an unbiased manner, we used a mouse Genome-Scale CRISPR/Cas9 Knockout
(GeCKO) library and screened for monocytes with reduced or absent S100A9 expression. We thereby identified the CCAAT/enhancer-binding protein-family member C/EBPδ as a direct transcriptional regulator of S100a8 and S100a9. Furthermore, we found that the epigenetic factor JMJD3 contributes to S100a8 and S100a9 expression in monocytes by erasure of the repressive histone mark H3K27me3 at S100a8 and S100a9 promoter regions. Moreover, we confirmed the biomedical relevance of this network a murine model of ALI and in specific monocyte subpopulations in a clinical cohort of patients with cardiovascular disease.

Results

Genome-wide CRISPR/Cas9 knockout screen reveals C/EBPδ as a regulatory factor of S100A9 expression

To detect genes involved in the regulation of S100a8 and S100a9 expression, we established the mouse GeCKO lentiviral pooled library designed in Cas9-expressing ER-Hoxb8 cells. The used library contained a large mixture of CRISPR sgRNA constructs, where six gRNAs per target gene increase efficiency and enable the analysis of the molecular effects of many thousand genes in one experiment. After infection of Cas9-expressing ER-Hoxb8 precursor cells with CRISPR library lentiviral particles, the cells were differentiated for 3 days in the presence of GM-CSF to induce S100A8 and S100A9 expression. Because we hypothesized that the parallel S100A8 and S100A9 expression is based on a common regulatory mechanism, we assumed that screening of one of the two alarmins was sufficient in the first step. Therefore, cells with no or low S100A9 expression were selected by sorting and considered as hits, whereas the remaining cells functioned as reference cells. To exclude phenotypes that were S100A9low/neg due to general differentiation defects, we pre-gated for CD11b+Ly-6C+ monocytes. DNA as hits, whereas the remaining cells functioned as reference cells. To exclude phenotypes that were S100A9low/neg due to general differentiation defects, we pre-gated for CD11b+Ly-6C+ monocytes.

To detect genes involved in the regulation of S100a8 and S100a9 expression, we established the mouse GeCKO lentiviral pooled library designed in Cas9-expressing ER-Hoxb8 cells. The used library contained a large mixture of CRISPR sgRNA constructs, where six gRNAs per target gene increase efficiency and enable the analysis of the molecular effects of many thousand genes in one experiment. After infection of Cas9-expressing ER-Hoxb8 precursor cells with CRISPR library lentiviral particles, the cells were differentiated for 3 days in the presence of GM-CSF to induce S100A8 and S100A9 expression. Because we hypothesized that the parallel S100A8 and S100A9 expression is based on a common regulatory mechanism, we assumed that screening of one of the two alarmins was sufficient in the first step. Therefore, cells with no or low S100A9 expression were selected by sorting and considered as hits, whereas the remaining cells functioned as reference cells. To exclude phenotypes that were S100A9low/neg due to general differentiation defects, we pre-gated for CD11b‘Ly-6C’ monocytes. DNA of sorted cell pools was purified and analysed by NGS (Figure 1A). Intracellular S100A9-FITC staining of precursor and differentiated Cas9 ER-Hoxb8 control monocytes was used as standard for definition of sorting gates. Differentiated Cas9-library ER-Hoxb8 monocytes showed a wider distribution among the gates, indicating the presence of S100A9low/neg expressing cells due to disruptions of regulatory genes caused by CRISPR/Cas9. A small amount of S100A9neg sorted cells were re-analysed by immunoblotting to validate S100A9 deficiency in this cell population (Figure 1B). Analysis of CRISPR KO library screen using the Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK) method (Li et al., 2014) resulted in a list of genes for which the respective gRNAs were enriched in the hits sample. The highest number of three gRNAs was found within the top 20 hits targeted Cebpd, a gene encoding for a member of the CCAAT/enhancer-binding protein family, C/EBPδ. Other gene hits, namely Manea, Htr1f, Ifit3, Phf8, Hand1, and Casp4, were targeted by two gRNAs (Figure 1C).

From these, those genes known to be involved in gene regulation, such as the transcription factors Cebpd and Hand1, as well as the histone demethylase Phf8, were selected for validation. Another transcription factor in the top 20 hit list, Csrp1, was targeted by only one gRNA but was chosen for validation due to its known functions in gene regulatory mechanisms (Kamar et al., 2017). Targeting Phf8, Hand1, and Csrp1 only slightly influenced S100a8 and S100a9 expression, whereas C/EBPδ deficiency strongly decreased S100a8 and S100a9 levels in differentiated monocytes (Figure 1—for supplement 1A). Interestingly, none of the transcription factors previously reported to target S100a8 and S100a9 (Kuruto-Niwa et al., 1998; Fujii et al., 2011; Lee et al., 2012; Liu et al., 2016; Yang et al., 2017) were found within the hit list of our CRISPR KO library screen (Figure 1—for source data 1). Nevertheless, to test the published candidate transcription factors ATF3, STAT3, KLF5, IRF7, and C/EBPδ for their effects on S100a8 and S100a9 regulation, we created single KO ER-Hoxb8 cell lines of each individual candidate transcription factor. Deficiency of none of the stated candidate transcription factors affects S100a8 and S100a9 expression during monocyte differentiation, whereas C/EBPδ deficiency had a strong attenuating effect on S100a8 and S100a9 expression, as shown on day 2 (Figure 1—for supplement 1B).

Decreased S100a8 and S100a9 expression in C/EBPδ KO monocytes

We confirmed extraordinarily high dynamics of S100a8 and S100a9 expression during monocyte/macrophage differentiation. ER-Hoxb8-derived monocytes showed about 590-fold increase in S100a8 mRNA expression and about 1800-fold increase of S100a9 mRNA expression on day 2 compared to
day 0 of differentiation. At day 5 the S100a8 mRNA expression is already about 70-fold and the S100a9 mRNA expression about 110-fold downregulated compared to day 2 of differentiation (Figure 2A, B).

We confirmed the relevance of C/EBPδ for S100a8 and S100a9 expression by creating independent C/EBPδ-deficient ER-Hoxb8 cells from C/EBPδ KO mice. Not only on differentiation day 3, but already at the very beginning of differentiation, when S100a8 and S100a9 levels start to rise, C/EBPδ-deficient ER-Hoxb8 monocytes showed significantly reduced levels of both S100a8 (Figure 2A) and S100a9 (Figure 2B) mRNAs compared to wildtype (WT) controls. The same effect was detectable in C/EBPδ-deficient ER-Hoxb8 cells that were differentiated into the neutrophilic lineage (Figure 2—figure supplement 1).
Figure 2. S100A8 and S100A9 expression in wildtype (WT) and C/EBPδ knockout (KO) monocytes. (A) Relative S100a8 and (B) S100a9 mRNA level during differentiation of WT and C/EBPδ KO ER-Hoxb8 monocytes were measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) (n=3–8). (C) S100A8/A9 concentrations in supernatant of differentiation day 4 of WT and C/EBPδ KO ER-Hoxb8 monocytes stimulated with 10 ng LPS for 4 hr or left untreated (n=3) were quantified using our in-house mouse S100A8/S100A9 sandwich enzyme-linked immunosorbent assay (ELISA) (n=6). (D) Relative S100a8 and S100a9 mRNA levels of bone marrow-derived mouse monocytes were measured using qRT-PCR (n=3). (E) Serum and (F) bronchoalveolar lavage fluid (BALF) of LPS- (WT: n=9, C/EBPδ KO: n=11) or NaCl-only (WT: n=6, C/EBPδ KO: n=3) exposed mice were harvested 4 hr after onset of lung inflammation and were analysed for S100A8/A9 expression, (G) for amount of recruited polymorphonuclear leukocytes (PMNs) and for (H) IL-1α, (I) IL-6, and (J) TNF-α production in BALF. Values are the means ± SEM. *p<0.05, **p<0.01, ***p<0.001, by two-tailed Student’s t test (A–C, H–J) and by one-way ANOVA with Bonferroni’s correction (E–G). See also Figure 2—figure supplements 1 and 2.

Figure 2 continued on next page
supplement 1A). Accordingly, Cebpd and S100a8 and S100a9 mRNAs were co-expressed in differentiating WT monocytes and neutrophils, supporting a mechanistic connection (Figure 2—figure supplement 1B, C). WT ER-Hoxb8 monocytes secreted significant S100A8/A9 protein amounts, whereas the supernatant of C/EBPδ KO cells contained up to 80% less S100A8/A9 (Figure 2C). Accordingly, S100a8 and S100a9 expression was decreased upon C/EBPδ deletion in primary bone marrow-derived monocytes (Figure 2D). To confirm that C/EBPδ deficiency affects alarmin expression and disease progression in vivo, we used a mouse model for acute lung inflammation. S100A8/A9 levels are locally increased in acute respiratory distress syndrome patients (Lorenz et al., 2008) and have been shown to play a role in neutrophil recruitment during ALI in mice (Chakraborty et al., 2017). Serum and bronchoalveolar lavage fluid (BALF) from LPS-exposed mice showed highly increased S100A8/A9 levels compared to control mice. In C/EBPδ KO mice, alarmin levels were systemically (serum) and locally (BALF) decreased compared to WT mice at baseline (NaCl) and after LPS exposure (Figure 2E, F), confirming our in vitro data. Accordingly, in BALF neutrophil recruitment (Figure 2G), as well as in IL-1α and IL-6, cytokine production was significantly decreased in LPS-exposed C/EBPδ KO mice in relation to WT littermates (TNF-α shows a similar trend, Figure 2H-J), which highlights the impact of S100A8/A9 on the disease outcome.

Inflammatory capacities and differentiation kinetics are unaffected in C/EBPδ KO monocytes

Although the proinflammatory molecule S100A8/A9 was strongly reduced in the C/EBPδ KO monocytes, these cells exhibited no general alterations of inflammatory functions, indicating a rather specific effect on S100a8 and S100a9 regulation than a general attenuation of inflammatory signaling due to C/EBPδ deficiency. Phagocytosis capacities, examined by using FITC-coupled Latex Beads (Figure 3A, B) and by using Staphylococcus aureus (Figure 3C, D), were even elevated in C/EBPδ KO monocytes. These observations were accompanied by enhanced gene expression of phagocytosis-related PRRs, such as Pttx3, CD209a, and Cd14, in C/EBPδ KO monocytes (Figure 3—figure supplement 1A, B, D). ROS production was not influenced by C/EBPδ deficiency (Figure 3E). Moreover, analysis of differentiation kinetics revealed no exorbitant differences in the quantities of CD11b^Ly-6C^ between WT and C/EBPδ KO cells, neither during differentiation of bone marrow-derived cells (BMCs) nor of ER-Hoxb8 cells (Figure 3F). With regard to monocyte differentiation and polarization capacities, we tested the effect of C/EBPδ deficiency in primary bone marrow-derived mouse monocytes (BMDMs). Whereas expression of M1-monocyte associated markers, such as Tnfa, Il6, Inos, Cd86, and Cd11b, was only slightly decreased in LPS- and IFN-γ-treated C/EBPδ KO monocytes in vitro (Figure 3—figure supplement 2A), M2-associated Il10 expression was significantly decreased upon IL-4-stimulation in C/EBPδ KO cells confirming earlier results (Liu et al., 2003). Expression of Cd163 showed no significant effect in C/EBPδ KO cells (Figure 3—figure supplement 2B). Decreased IL-10 expression was also found in sera from LPS-treated and control C/EBPδ KO mice, whereas most other cytokine levels did not differ greatly between WT and C/EBPδ KO mice (Figure 2—figure supplement 2).

Enhanced C/EBPδ expression induces S100a8 and S100a9 expression

To test the impact of C/EBPδ induction on S100 alarmin expression, we infected C/EBPδ-deficient ER-Hoxb8 cells with lentiviral particles carrying a Tet-On system for doxycycline-inducible 3xFlag-C/EBPδ expression (Figure 4A). Doxycycline treatment led to expression of the fusion protein 3xFlag-C/EBPδ, as revealed by western blot analysis (Figure 4B) and by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in comparison to C/EBPδ-deficient cells (Figure 4C). Induction of 3xFlag-C/EBPδ upon doxycycline treatment led to increased S100a8 and S100a9 mRNA levels. Cebpd, S100a8, and S100a9 mRNA levels in doxycycline-treated TRE_3xFlag-C/EBPδ cells were comparable to WT cells at the same differentiation stage (Figure 4D), demonstrating a positive effect of C/EBPδ expression on S100a8 and S100a9 regulation. KO of ATF3, a known regulatory attenuator of Cebpd
expression (Litvak et al., 2009), in ER-Hoxb8 monocytes led to S100a8 and S100a9 overexpression (Figure 4E, Figure 1—figure supplement 1B), especially during early stages of differentiation. ATF3 KO cells showed significantly elevated cebpd level, indicating a C/EBPδ-mediated effect on the expression of S100a8 and S100a9 (Figure 4F). In the next step, we created FBXW7-deficient monocytes. FBXW7 is another well-known attenuator of C/EBPδ expression (Balamurugan et al., 2013). Lack of this antagonist resulted in an even higher overexpression of S100a8 and S100a9 (Figure 4G) with huge increases of Cebpd levels (Figure 4H).

To confirm the biomedical relevance of the identified molecular network, we analysed the expression of these genes in peripheral blood mononuclear cells (PBMCs) and monocyte subpopulations.
Figure 4. S100a8 and S100a9 expression in differentiated ER-Hoxb8 cells is dependent on C/EBPδ abundancy. (A) Tet-On construct of inducible 3xFlag-C/EBPδ expression due to constitutively expressed rtTA (reverse tetracycline-controlled transactivator) that binds to TRE promoter upon doxycycline treatment was transduced into C/EBPδ knockout (KO) ER-Hoxb8 cells. (B) Induction of 3xFlag-C/EBPδ upon doxycycline treatment (2 μg/ml, 24 hr) was analysed by western blot and (C) quantitative reverse transcription polymerase chain reaction (qRT-PCR) in comparison to untreated cells. (D) Induction of 3xFlag-C/EBPδ was also analysed by qRT-PCR (Cebpd), as well as expression of S100a8 and S100a9 mRNAs, in untreated and dox-treated C/EBPδ KO TRE_3xFlag-C/EBPδ monocytes and in comparison to wildtype (WT) and C/EBPδ KO monocytes on differentiation day 1 (n=3). (E, G) S100a8 and S100a9, (F, H) and Cebpd mRNA levels were measured using qRT-PCR in precursor and differentiated WT and ATF3 KO (E, F) and in WT and FBXW7 KO (G, H) ER-Hoxb8 monocytes (n=3–4). Values are the means ± SEM. *p<0.05, **p<0.01, by one-way ANOVA with Bonferroni’s correction (D) and by two-tailed Student’s t test (E–H).
A Gene expression changes detected by RNA-sequencing (RNA-seq) in peripheral blood mononuclear cells (PBMCs) of BioNRW participants (n=72, sCAD/MI vs. Ctrl). LFC = log2 fold change, SE = standard error, and adj.p = adjusted p-value.

| Gene     | LFC  | SE   | adj.p               | p-value |
|----------|------|------|---------------------|---------|
| CEBPD    | 0.348| 0.115| 1.71E-02            |         |
| S100A8   | 0.552| 0.128| 5.01E-04            |         |
| S100A9   | 0.568| 0.118| 1.12E-04            |         |

B Pearson correlation with CEBPD

| Gene     | n=72 | p   | r     |
|----------|------|-----|-------|
| S100A8   | 1.81E-09 | 0.637|
| S100A9   | 2.31E-10 | 0.663|

C Hierarchical clustering of CEBPD

D Expression changes in monocyte subpopulations

| Comparison | CEBPD     | S100A8     | S100A9     | ATF3     | FBXW7     |
|------------|-----------|------------|------------|----------|-----------|
| 1, Ctrl vs 2, Ctrl | 2.693 | 0.509 | 1.50E-06 | 2.751 | 0.477 | 1.21E-07 | n.s. | n.s. | n.s. | -0.877 | 0.254 | 2.74E-03 |
| 2, Ctrl vs 3, Ctrl | 4.130 | 0.509 | 1.84E-14 | 4.161 | 0.477 | 1.35E-16 | n.s. | n.s. | n.s. | -0.604 | 0.254 | 4.45E-02 |
| 3, sCAD vs 2, sCAD | 2.338 | 0.509 | 6.08E-05 | 2.795 | 0.477 | 1.97E-07 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| 4, sCAD vs 3, sCAD | 4.443 | 0.553 | 9.18E-14 | 4.225 | 0.520 | 4.47E-14 | -1.139 | 0.352 | 5.33E-03 | n.s. | n.s. | n.s. |
| 1, MI vs 2, MI | 2.342 | 0.509 | 4.74E-05 | 2.530 | 0.477 | 1.97E-06 | -1.200 | 0.321 | 1.17E-03 | -0.871 | 0.254 | 3.16E-03 |
| 2, MI vs 3, MI | 3.173 | 0.509 | 5.33E-09 | 3.415 | 0.477 | 1.52E-11 | n.s. | n.s. | n.s. | -0.668 | 0.254 | 2.32E-02 |

1 = classical MI = myocardial infarction SE = standard error adj.p = adjusted p-value
2 = intermediate sCAD = coronary artery disease LFC = log2 fold change
3 = non-classical Ctrl = healthy donors n.s. = not significant

E Hierarchical clustering of monocyte subsets

F Pearson correlation with CEBPD

| Gene     | n=26 | p     | r     |
|----------|------|-------|-------|
| S100A8   | 4.75E-08 | 0.847|
| S100A9   | 1.05E-09 | 0.891|
| ATF3     | 0.0107 | -0.49|
| FBXW7    | 0.0004 | -0.64|

G Hierarchical clustering of CEBPD

Figure 5. CEBPD expression positively correlates with S100A8 and S100A9 expression in proinflammatory monocytes of myocardial infarction/stable coronary artery disease (MI/sCAD) patients. (A) Gene expression changes detected by RNA-sequencing (RNA-seq) in peripheral blood mononuclear cells (PBMCs) of BioNRW participants (n=72, sCAD/MI vs. Ctrl). LFC = log2 fold change, SE = standard error, and adj.p = adjusted p-value. (B) Pearson correlation coefficient = r, p-value = p in PBMCs and (C) corresponding correlation matrix. (D) Gene expression changes of CEBPD, S100A8, S100A9, ATF3, and FBXW7 detected by RNA-seq in monocyte subpopulations of BioNRW participants (n=26, from three individuals in each of the sCAD, MI, and Ctrl diagnostic groups). (E) Hierarchical clustering of S100A8-, S100A9-, and CEBPD normalized counts (using Euclidean distance metric with complete linkage). Shown are classical (1), intermediate (2), and non-classical (3) monocytes of healthy donors (Ctrl), MI, and sCAD patients. (F) Pearson correlation coefficient = r, p-value = p in monocytes and (G) corresponding correlation matrix. See also Figure 5—source data 1.

Source data 1. Expression changes in the BioNRW monocytes dataset (RNA-sequencing [RNA-seq], n=26).

of a subset of participants in the BioNRW Study (Witten et al., 2022). Here, we found upregulation of S100A8, S100A9, and CEBPD in PBMCs of stable coronary artery disease/myocardial infarction (sCAD/MI) cases, compared against controls (Figure 5A), together with a positive correlation of S100A8 and S100A9 expression with that of CEBPD in these cells (Figure 5B, C). Moreover, there was also significant upregulation of these three genes specifically in classical monocytes, compared to intermediate and non-classical monocyte subpopulations (Figure 5D, E, for further comparisons, see Figure 5—source data 1). A strong positive correlation between the expression of S100A8 and S100A9 and CEBPD in these monocyte subpopulations was found, suggesting that the expression of these genes is mainly associated with the subset of proinflammatory monocytes. Interestingly, we also found significant albeit milder, negative correlations between the expression of CEBPD and its antagonists FBXW7 and ATF3 in monocytes (Figure 5F, G).
C/EBPδ-binding sites within S100a8 and S100a9 promoter regions

Chromatin immunoprecipitation (ChIP) revealed 3xFlag-C/EBPδ binding on S100a8 and S100a9 promoter regions just before or within the predicted enhancers (Figure 6A). Co-transfection of HEK293T cells with GFP-expressing S100 reporter vectors, together with doxycycline-inducible 3xFlag-C/EBPδ vector (TRE_3xFlag-C/EBPδ) or its backbone lacking the 3xFlag-C/EBPδ construct (TRE_ctrl), was performed to further examine specific C/EBPδ binding (Figure 6B). Doxycycline treatment resulted in 3xFlag-C/EBPδ protein expression after 24 hr post-transfection in 3xFlag-C/EBPδ vector transfected cells (Figure 6C). Transfection of either S100a8 reporter construct (Figure 6D) or S100a9 reporter construct (Figure 6F) together with 3xFlag-C/EBPδ vector led to enhanced GFP expression upon doxycycline treatment in comparison to co-transfection with backbone plasmid (TRE_ctrl). Next, we modified predicted C/EBP-binding sites on S100 promoters by mutagenesis of the corresponding vectors. Again, co-transfection of mutated S100 reporter vectors and doxycycline-dependent 3xFlag-C/EBPδ vector was performed to analyse the relevance of specific C/EBPδ-binding sites. Two sites within the S100a8 promoter region, stated as site 2 and site 3 (Figure 6E), and one within the S100a9 promoter region, stated as site 4 (Figure 6G), caused a reduced or absent GFP expression upon co-transfection when deleted. These binding sites, in turn, were located within the S100a8 and S100a9 promoter regions where C/EBPδ binding was confirmed by ChIP (Figure 6A).

Epigenetic landscape on S100 promoter regions reflects S100a8 and S100a9 expression in monocytes

Regulation of gene expression relies on variable factors; among these are chromatin structure and epigenetic features. To measure changes in chromatin accessibility in monocytic progenitors and in S100a8- and S100a9-expressing monocytes, we performed ATAC-seq of precursor and differentiated WT and C/EBPδ KO ER-Hoxb8 cells. This revealed over 1000 regions with differential peaks in all comparisons (Figure 7A and Figure 7-figure supplement 1). Among the regions with significantly higher ATAC-seq reads in differentiated samples at day 3 of WT cells were the S100a8 and S100a9 promoter and enhancer locations. Interestingly, within these regions chromatin accessibility was significantly decreased in C/EBPδ KO in comparison to WT cells at day 3 of differentiation (Figure 7B, C). Consistent with the changes in chromatin accessibility at S100 promoter regions during differentiation, we also found changes in histone marks by ChIP. H3K27 acetylation (H3K27ac), a marker for active transcription, was increased at differentiation day 3 of monocytes over precursor cells at S100a8 (Figure 7D) and S100a9 loci (Figure 7E) in both, WT and C/EBPδ KO cells. In contrast, tri-methylated H3K27 (H3K27me3), associated with gene silencing, was overrepresented in precursor cells over differentiated cells at the same loci in WT cells, whereas H3K27me3 marks did not decrease over the course of differentiation in C/EBPδ KO cells. Accordingly, tri-methylated H3K27 was increased in C/EBPδ KO monocytes, compared to the WT counterparts (Figure 7F, G).

The histone demethylase JMJD3 drives S100a8 and S100a9 expression in dependency of C/EBPδ

Decreased S100a8 and S100a9 expression in C/EBPδ-deficient day 3 monocytes was mirrored in the epigenetic landscape by only slightly decreased H3K27ac level, but highly increased H3K27me3 level at S100 promoter regions. Erasure of tri-methylation and di-methylation at H3K27 is known to be catalysed by the histone demethylase JMJD3 (JmjC Domain-Containing Protein 3) (Xiang et al., 2007). We found decreased expression of Jmjd3 in differentiated C/EBPδ KO monocytes, compared to WT cells at the same stage (Figure 8A). Further, we used the potent JMJD3 inhibitor GSK-J4 (Kruide- nier et al., 2012) to block H3K27 demethylation in differentiating ER-Hoxb8 cells, and discovered significantly decreased S100a8 and S100a9 expression in GSK-J4-treated WT cells (Figure 8B). These mRNA quantities were comparable to untreated C/EBPδ-deficient monocytes, whereas the effects on S100a8 and S100a9 expression in GSK-J4-treated C/EBPδ-deficient monocytes, compared to the untreated counterparts, were negligible (Figure 7B). These effects of GSK-J4 on S100a8 and S100a9 expression are in line with increased H3K27me3 marks in GSK-J4-treated WT monocytes, compared to untreated WT cells on both, S100a8 (Figure 8C) and S100a9 (Figure 8D) promoter regions.
Figure 6. C/EBPδ binds to regions within the S100a8 and S100a9 promoters. (A) Chromatin immunoprecipitation was performed in untreated (-) and dox-treated (+dox) TRE_3xFlag-C/EBPδ monocytes on differentiation day 1 using a Flag-antibody. Purified DNA was analysed using primer pairs flanking different S100a8 and S100a9 promoter and intronic regions and a negative control primer pair flanking a random genomic region (n=3). (B) Co-transfection of vectors carrying constructs for GFP under the S100a8 or S100a9 promoter (reporter), together with the doxycycline-dependent 3xFlag-C/EBPδ/Tubulin reporter.
Discussion

The ER-Hoxb8 cell system serves as a substitute for murine primary cells of myeloid origin that can be differentiated into phagocytes, such as monocytes and neutrophils. It reflects reliably the differentiation of myeloid progenitor cells to bone marrow-derived monocytes and macrophages. Due to the high expression of S100A8 and S100A9 in the early days of culture around day 3, we describe these stage as monocytes, later days of differentiation with no or low expression of these S100 proteins as macrophages in analogy to the human system. This system allows comparison with in vitro differentiated primary cells (Wang et al., 2006a) and, therefore, provides an experimental cell model for analysis of S100A8 and S100A9 expression. Although the alarmins are regarded as key factors in various inflammatory conditions (Foell and Roth, 2004), cancer types (Cross et al., 2005), and cardiovascular diseases (Frangogiannis, 2019), little is known about their transcriptional regulation. The serum concentrations of alarmins correlate with disease severity and activity and, hence, they are reliable biomarkers for monitoring several inflammatory diseases (Foell et al., 2004; Ehrchen et al., 2009). The expression levels of S100a8 and S100a9 differ extremely during myeloid differentiation and the promoters of their genes represent probably one of the most dynamic regulatory elements in the myeloid lineage. Whereas both proteins are completely absent in myeloid precursor cells, they are highly expressed in monocytes and neutrophils, which suggests that highly dynamic regulatory mechanisms drive S100a8 and S100a9 expression.

The CRISPR/Cas9-mediated KO screening approach based on a lentiviral pooled library has been used so far to investigate various mechanisms, such as immunity-related pathways and cancer-modulating events (Kweon and Kim, 2018). In this study, our unbiased genome-wide screening approach allowed the identification of C/EBPδ as a factor involved in S100A9 regulation during murine monocyte differentiation. We further focused our investigations on Cebpδ because this gene was in the top list of the robust rank aggregation (RRA) scores and showed the highest numbers of guide RNAs with efficient effects on S100A9 expression in our screening. This redundancy of independent parameters helped to distinguish true positive from false positive hits. Furthermore, a robust phenotype-of-interest, such as a clear S100A9 protein signal at day 3 of monocyte differentiation, allowed reliable negative selection in Cas9-library monocytes. Selection of remaining cells served as a reference control to distinguish true from false positives. The specificity of our selection procedure was confirmed at the protein level by western blot analysis of sorted cell populations. CRISPR/Cas9-based functional genomic screening has been reported to be highly specific, thereby causing fewer cases of false positives in direct comparison with knockdown analysis by RNA interference (Shalem et al., 2014). We were now able to identify a novel regulator of S100A8 and S100A9 using this unbiased method. By pre-gating on CD11b+Ly-6C+ monocytes, we revealed C/EBPδ as a specific and differentiation-independent regulator of S100A8 and S100A9, excluding pathways linked to general functions or development of phagocytes. Re-analysis of S100A9 expression by immunoblotting of sorted cell populations verified the gates set (Figure 1B). However, validation of four candidate genes from our hit list demonstrates the limitation of the CRISPR screening system. Not every targeted hit, such as Phf8, Hand1, and Csrp1, showed a prominent effect on S100a8 and S100a9 expression. Possibly, the slight differences are rather due to indirect effects on S100 expression than due to deficiency of actual direct regulators. Another interesting gene within our top 20 hit list is the transcription factor creb1 (Figure 1C) that is known to mediate cytokine signaling at least in human neutrophils and could therefore be tested for S100a8 and S100a9 regulation in future experiments (Mayer et al., 2013). Known regulators of S100A8 and S100A9 that are also essential for general differentiation, such as PU.1 (Xu et al., 2021), were very likely excluded due to our monocyte pre-gating strategy.

Our data indicate that this screening technique seems not optimal enough to identify all factors of an
Figure 7. Analysis of chromatin accessibility and epigenetic features within S100a8 and S100a9 promoter regions. Assay for transposase-accessible chromatin using sequencing (ATAC-seq) was executed in precursor (day 0=d0) and differentiated (day 3=d3) wildtype (WT) and C/EBPδ knockout (KO) ER-Hoxb8 monocytes. (A) Differential peak analysis between all conditions was performed (n=3). (B) Combined gene tracks showing ATAC-seq reads of precursor (day 0) and differentiated (day 3) WT and C/EBPδ KO cells at the S100a8 and S100a9 gene regions. (C) Differential accessibility at
interrelated regulatory protein complex, but it is sufficient for unbiased detection of single factors for gene regulation, as shown in our study.

We confirmed that the transcription factor C/EBPδ is a direct regulator of S100A8 and S100A9 in murine monocytes using independent approaches. Cebpd, and S100a8 and S100a9 were co-expressed in differentiating monocytes, and induction of C/EBPδ clearly showed that the expression of S100a8 and S100a9 was upregulated by the presence of C/EBPδ. This evidence was further supported by increased S100a8 and S100a9 levels caused by deletion of ATF3 and FBXW7, which are natural inhibitors of C/EBPδ. There is a parallel decrease of Cebpd, and S100a8 and S100a9 expression during later stages of monocyte/macrophage differentiation which may point to a functional relation of C/EBPδ expression and downregulation of S100 expression as well. However, the late expression kinetics of S100a8 and S100a9 in WT and C/EBPδ KO cells clearly point to the presence of additional relevant factors which were not addressed by our screening approach.

**Figure 7 continued**

S100a8 and S100a9 loci was analysed for all comparisons. Chromatin immunoprecipitation was performed using anti-H3K27ac (D, E), anti-H3K27me3 (F, G) in chromatin of precursor (day 0) and differentiated (day 3) WT and C/EBPδ KO (KO) ER-Hoxb8 monocytes. Purified DNA was analysed using primer pairs flanking different S100a8 (D, F) and S100a9 (E, G) promoter regions (n=3–6). N-folds are based on percent of input values of respective day 0 ChIP-PCR samples. Values are the means ± SEM. *p<0.05, **p<0.01, ***p<0.001, ns = not significant, by one-way ANOVA with Bonferroni’s correction. See also Figure 7—figure supplement 1 and Figure 7—source data 1.

The online version of this article includes the following source data and figure supplement(s) for figure 7:

**Source data 1.** Differential peak analysis based on assay for transposase-accessible chromatin using sequencing (ATAC-seq) data of wildtype (WT) and C/EBPδ knockout (KO) day 0 and day 3 ER-Hoxb8 cells.

**Figure supplement 1.** Differential peak analysis based on assay for transposase-accessible chromatin using sequencing (ATAC-seq) data of wildtype (WT) and C/EBPδ knockout (KO) day 0 and day 3 ER-Hoxb8 cells.

---

**Figure 8.** JMJD3-mediated demethylation of H3K27me3 is crucial for S100a8 and S100a9 expression. (A) Jmjd3 mRNA levels of precursor and differentiated wildtype (WT) and C/EBPδ knockout (KO) ER-Hoxb8 cells were analysed using quantitative reverse transcription polymerase chain reaction (qRT-PCR) (n=3). (B) WT and C/EBPδ KO ER-Hoxb8 cells were treated with 5 μM GSK-J4 for 3 days during differentiation and S100a8 and S100a9 mRNA levels were analysed using qRT-PCR (n=5). Chromatin immunoprecipitation was performed using anti-H3K27me3, and appropriate IgG control antibodies in chromatin of vehicle controls (-) and treated (+GSK-J4) WT and C/EBPδ KO (KO) ER-Hoxb8 monocytes. Purified DNA was analysed using primer pairs flanking different S100a8 (C) and S100a9 (D) promoter regions (n=3–5). Values are the means ± SEM. *p<0.05, **p<0.01, ***p<0.001, ns = not significant, by one-way ANOVA with Bonferroni’s correction (A, B) or by two-tailed Student’s t test in comparison to WT (-) (C, D).
The specificity of our approach was further confirmed by the fact that deficiency of several transcription factors, such as STAT3, KLF5, IRF7, and C/EBPδ, described as S100A8 and S100A9 regulators in previous studies (Kuruto-Niwa et al., 1998; Fujiu et al., 2011; Lee et al., 2012; Liu et al., 2016; Yang et al., 2017), did neither affect S100a8 and S100a9 expression in our ER-Hoxb8 monocytes, nor were these listed as gene hits in our CRISPR/Cas9-mediated KO screening approach. Our ChIP data clearly showed that C/EBPδ specifically binds within S100a8 and S100a9 promoter regions. Co-transfection of an inducible C/EBPδ construct and S100a8 and S100a9 reporter constructs not only demonstrated S100 promoter activation due to C/EBPδ expression, but also revealed functional relevance of specific binding sites, via promoter bashing, that are located exactly within the stated promoter regions. The two DNA motifs for specific C/EBPδ responses on the S100a8 promoter regions did not share the core sequence 5′-C/G GCATT-3′ that we found within the S100a9 promoter region in our study. The latter has been described in three other promoters, the human PPARG2 promoter (Lai et al., 2008), the murine and human CEBPD promoter itself (Wang et al., 2021), and the human COX2 promoter (Wang et al., 2006b). We were able to show that the functionally relevant C/EBPδ-binding sites within the S100 promoters lie within genome regions which switch from closed to open chromatin states during monocyte differentiation, and concomitant induction of S100 expression as examined by ATAC-seq.

Our chromatin accessibility data on S100a8 and S100a9 promoter regions reflected active S100a8 and S100a9 transcription on day 3 cells and accurately mirrored decreased S100 expression of C/EBPδ KO monocytes in relation to WT counterparts. These observations were again reflected and supported by the characterization of the epigenetic landscape using H3K27ac and H3K27me3 marks. The fact that H3K27me3 marks were strongly decreased in WT monocytes, but not in precursors or C/EBPδ-deficient monocytes, showed the indispensability of H3K27 demethylation for S100a8 and S100a9 expression. Moreover, our data demonstrated that the Jumonji C family histone demethylase JMJD3 regulates S100a8 and S100a9 expression by erasure of H3K27me3 in dependency of C/EBPδ, which was confirmed by GSK-J4-mediated inhibition of JMJD3 activities. Neither a link of C/EBPδ nor of S100A8/A9 and JMJD3 has been published yet. It has been shown that histone demethylase activities of recombinant JMJD3 on mono-nucleosome substrates is relatively low in contrast to higher activities on bulk histones (Lan et al., 2007), suggesting that further factors, such as C/EBPδ, are involved in chromatin binding. Several studies highlight JMJD3 as a regulator of innate immune responses, especially via NF-kB-mediated inflammation in macrophages (Na et al., 2016; Na et al., 2017; Davis et al., 2020). Accordingly, knockdown of JMJD3 affected mainly inflammatory response networks in monocyctic THP-1 cells (Das et al., 2012) and blocked activation of the NLRP3 inflammasome in bone marrow-derived macrophages (Huang et al., 2020). GSK-J4 treatment of mice attenuated disease progression and inflammatory activities in several mouse models for inflammatory diseases, such as arthritis (Jia et al., 2018), colitis (Huang et al., 2020), and EAE (experimental autoimmune encephalomyelitis) (Doñas et al., 2016). Accordingly, GSK-J4 treatment of our ER-Hoxb8 monocytes reduced expression of the proinflammatory alarmins S100a8 and S100a9, which have been shown to drive the inflammatory process of arthritis (van Lent et al., 2012). With our study, we have taken a step forward to uncover the role of epigenetic features on S100a8 and S100a9 expression and, thereby, on inflammatory conditions in murine monocytes.

We were also able to demonstrate an association of CEBPD, and S100A8 and S100A9 expression in the context of human cardiovascular disease. The expression of these molecules shows a significant positive correlation not only to each other but also to the manifestation of sCAD and MI in patient-derived PBMCs. Moreover, expression of CEBPD, S100A8 and S100A9 showed an even stronger association with classical, proinflammatory monocytes (CD14+CD16−), compared to non-classical (CD14+CD16+) and intermediate (CD14+CD16+) monocytes. The endogenous antagonists of C/EBPδ, ATF3 and especially FBXW7, showed a negative correlation of their expression pattern in these monocyte subpopulations. Interestingly, inflammatory monocytes with phagocytic and protelytic activities have been reported to show an early peak at infarct sites, which are followed by infiltration of non-classical, anti-inflammatory monocytes (Nahrendorf et al., 2007; Dutta and Nahrendorf, 2015). Genetic deletion of S100A8/A9 was reported to attenuate MI and improve cardiac function in murine models. In contrast, overexpression of S100a9 in mice increased infarct size and mortality, and treatment with recombinant S100 proteins raised influx of immune cells into the infarct area (Li et al., 2019; Sreejit et al., 2020). Moreover, serum concentrations of S100A8/A9 are known to be highly
sensitive and prognostic markers for myocardial injury (Aydin et al., 2019). Taken together, these data indicate that the C/EBPδ-S100 alarmin axis drives a clinically relevant pathomechanism in cardiovascular disease and probably other inflammation-driven conditions.

There are several published reports suggesting a biomedical relevance of the link between the C/EBPδ and the S100A8/A9 alarmin under other inflammatory conditions as well. For example, C/EBPδ has been shown to play a role in the pathogenesis of psoriasis (Lan et al., 2020) and in acute inflammatory signaling by regulating COX-2 (Wadleigh et al., 2000), IL-6 (Litvak et al., 2009), and TLR4 (Balamurugan et al., 2013). Analysis of the genome-wide transcription pattern of monocytes revealed IL6 as the top gene induced by S100 alarmin stimulation via interaction with TLR4 (Fassl et al., 2015), and targeted deletion of S100A9 ameliorated inflammation in a murine psoriasis model (Zenz et al., 2008). Additionally, C/EBPδ levels were elevated in mouse models and patients of Alzheimer’s disease (AD) (Li et al., 2004; Ko et al., 2012) and RA (Nishioka et al., 2000; Chang et al., 2012). In mouse models of AD, downregulation (Ha et al., 2010) and deficiency of S100A9 (Kummer et al., 2012) had therapeutic effects on disease activity. Also in human studies, S100A9 was found to be associated with AD pathogenesis (Shepherd et al., 2006). Beyond that, S100A8 and S100A9 are known key players in the pathogenesis of arthritis in murine models (van Lent et al., 2012). Gene expression profiling of blood cells from RA patients receiving anti-TNF-α-based treatment showed that both CEBPD and S100A8 were downregulated by the treatment (Meugnier et al., 2011). Uncontrolled activity of S100A8/A9 alarmins drives TNF-induced arthritis in mice (Vogl et al., 2018). In the context of human RA, the expression and serum concentrations of S100A8/A9 correlate very well with disease activity and are the first predictive marker for disease relapses in juvenile patients, and of the responses to therapy in juvenile and adult patients (Moncrieffe et al., 2013; Choi et al., 2015). However, no direct molecular or functional link between S100A8/A9 and C/EBPδ in arthritis has yet been reported. Using an in vivo model for acute lung inflammation, we were now able to show that C/EBPδ-deficient mice express lower S100A8/A9 level than WT littermates in response to LPS exposure, which is accompanied by a milder disease phenotype. In S100A9 KO mice, neutrophil recruitment in the lung was impeded when using the same mouse model (Chakraborty et al., 2017), suggesting that S100A8/A9 expression mediates effects of C/EBPδ as a key mediator of LPS-induced lung inflammation (Yan et al., 2013). Our data define a new regulatory axis between the transcription factor C/EBPδ and the alarmins S100A8 and S100A9 in myeloid cells which is of relevance in different inflammatory processes and clinical diseases.

Materials and methods

Murine model of acute lung inflammation

WT and C/EBPδ KO (kindly provided by Esta Sterneck, National Cancer Institute, Frederick, MD) (Sterneck et al., 1998) mice were exposed to LPS from Salmonella enterica (0.5 mg/ml, Sigma-Aldrich) in saline or saline (NaCl) only for 45 min inside a cylindrical Pyrex chamber which was connected to a nebulizer. After a 4 hr resting period, mice were anesthetized, blood was collected from heart and BALF was collected for S100A8/A9 measurements by flushing the lungs five times with 0.8 ml NaCl through a nebulizer. Serum and BALF were saved for later analyses of alarmins and cytokines at −80°C. Migrated polymorphonuclear leukocytes were analysed via Kimura and following Ly-6B.2/Gr-1− antibody (Bio-Rad) staining. Mouse experiments were in accordance with German Animal Welfare Legislation and performed as approved by the North Rhine-Westphalia Office of Nature, Environment and Consumer Protection (LANUV), and the District Government and District Veterinary Office Muenster under the reference number 81-02.04.2019.A445.

Cell culture

ER-Hoxb8 cells were generated as described earlier (Wang et al., 2006a) and grown in RPMI medium (Thermo Fisher Scientific) supplemented with 10% FBS (Biowest), 1% penicillin/streptomycin solution (Sigma-Aldrich), 1% glutamine solution (Thermo Fisher Scientific), 40 ng/ml recombinant mouse GM-CSF (ImmunoTools) an 1 μM β-estradiol (Sigma-Aldrich). For differentiation, precursor cells were washed and incubated in estradiol-free medium containing 40 ng/ml GM-CSF for several days. HEK293T were grown in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (Biowest) and 1% penicillin/streptomycin solution (Sigma-Aldrich), 1% glutamine solution (Thermo Fisher Scientific),
and 1% sodium pyruvate (Merck). All cell lines were cultured at 37°C, 5% CO2, and routinely screened and found negative for mycoplasma contamination in a PCR-based assay (PromoCell).

**Cell line generation and manipulation**

WT, C/EBPδ KO (kindly provided by Esta Sterneck, National Cancer Institute, Frederick, MD; Sterneck et al., 1998) and Cas9-expressing (Chiou et al., 2015) ER-Hoxb8 cells originated from corresponding mice. PHF8, CSRP1, HAND1, FBXW7, ATF3, STAT3, KLF5, IRF7, and C/EBPδ KO ER-Hoxb8 cells were generated using CRISPR/Cas9 as described earlier (Gran et al., 2018). The oligos for gRNA cloning are listed in Supplementary file 1a. For lentiviral production, the lentiGuide-Puro (for GeCKO screen), lentiCRISPRv2-gRNA (for single KO cell lines), or TRE_3xFlag-CEBPδ was co-transfected into HEK293T cells, together with the packaging plasmids pCMV-VSV-G (AddGene, #8454) and psPAX2 (AddGene, #12260). For transduction of ER-Hoxb8 cells, cells were incubated with lentiviral particles and 8 µg/ml polybrene (Sigma-Aldrich) for 1 hr upon spinfection and selected for several days using puromycin (InvivoGen). For transfection of HEK293T cells, the cells were seeded 1 day prior to transfection. Then, cells were co-transfected with TRE_3xFlag-CEBPδ and S100a8 reporter or S100a9 reporter using the Lipofectamine 3000 Transfection Reagent (Thermo Scientific) according to the manufacturer’s manual. For inhibition of JMJD3 activities, cells were treated using 5 µM GSK-J4 HCl (SelleckChem) for 3 days. To induce cebpd in TRE_3xFlag-CEBPδ ER-Hoxb8 cells or transfected HEK293T cells, cells were treated using 2 µg/ml doxycycline (Sigma-Aldrich) for 24 hr.

**Isolation of BMDMs**

BMDMs were obtained by flushing the femurs from WT and C/EBPδ KO mice. Erythrocytes were depleted by osmotic shock. Cells were washed and separated using a Ficoll gradient (PAN-Biotech). Primary monocytes (M0) were generated by culturing for 3 days in DMEM containing 10% FBS (Biowest) and 1% penicillin/streptomycin solution (Sigma-Aldrich), 1% glutamine solution (Thermo Fisher Scientific), and 15% of L929 supernatant as a source of macrophage colony-stimulating factor. Stimulation of cells with 50 ng/ml IFN-γ (ImmunoTools) and 10 ng/ml LPS (Sigma-Aldrich) for 24 hr was used for M1-polarization, whereas a 24 hr stimulation with 20 ng/ml IL-4 (Peprotech) led to M2-polarization of BMDMs.

**GeCKO-library screening**

Amplification of mouse CRISPR Knockout pooled library (GeCKO v2) in lentiGuide-Puro plasmid, purchased from AddGene (#1000000053) (Sanjana et al., 2014), was performed as described (Joung et al., 2017). Cas9-expressing ER-Hoxb8 cells, transduced with library lentiviral particles at an MOI of 0.4, were differentiated to day 3. Intracellular S100A9 was stained with an S100A9-FITC coupled antibody using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Cells with no/lower S100A9 expression (hits) and cells with normal S100A9 expression (reference) were sorted using an SH800S Cell Sorter (Sony, Minato, Japan) and DNA was purified by phenol-chloroform extraction. Next-generation sequencing was performed as described earlier (Joung et al., 2017). Briefly, sgRNA library for next-generation sequencing was prepared via PCR using primers amplifying the target region with Illumina adapter sequences (Supplementary file 1b), the purified DNA, and the NEBNext High-Fidelity 2× PCR Master Mix (NEB). PCRs were pooled and purified using the QIAquick PCR Purification Kit (Qiagen). Size and quantity was determined using the Bioanalyzer High Sensitivity DNA Analysis Agilent High Sensitivity DNA Kit (Agilent). Sequences were sampled using the Illumina user manual with 80 cycles of read 1 (forward) using the NextSeq 500/550 High Output Kit v2.5 (75 Cycles) (Illumina) with the 20% PhiX spike in Illumina PhiX control kit (Illumina).

**Cloning and plasmid production**

TRE_3xFlag-C/EBPδ and TRE_ctrl

The pcDNA 3.1(−) mouse C/EBPδ expression vector (AddGene, #12559) and annealed oligonucleotides (Supplementary file 1c) were digested using XbaI and EcoRI and then ligated. Using primers carrying restriction enzyme recognition sites (Supplementary file 1c), the 3xFlag-C/EBPδ expression cassette was amplified. The resulting amplicon and the pCW57.1 mDux-CA target vector (AddGene, #99284) (Whiddon et al., 2017) were digested using Nhel and Agel and subsequently ligated. TRE_ctrl was produced by digesting TRE_3xFlag-C/EBPδ using Nhel and Agel and by subsequent blunting...
of ends by 3’ overhang removal and fill-in of 3’ recessed (5’ overhang) ends using DNA Polymerase I, Large (Klenow) Fragment (NEB) prior to ligation.

**S100a8 and S100a9 reporter**

To construct S100 reporter vectors, 1500 bp upstream of S100a8 and 1800 bp upstream of S100a9 TSS were amplified from genomic mouse DNA. Using primers carrying restriction enzyme recognition sites (*Supplementary file 1d*), promoter regions were amplified and cloned into pLenti CMV GFP Blast vector (AddGene, #17445) (*Campeau et al., 2009*) using XbaI and ClaI. Resulting S100 prom-GFP constructs were cloned into MSCV-PIG-empty vector (AddGene, #105594) (*Xu et al., 2018*) by digestion with NsiI and ClaI together with the MSCV backbone to exchange IRES-GFP-cassette with S100a8/a9prom-GFP-cassette and subsequent ligation. Proposed C/EBP DNA-binding sites within S100a8 and S100a9 promoter regions were identified using the AliBaba2.1 net-based transcription factor-binding site search tool (*Grabe, 2002*), and were mutated by deleting 6–7 base pairs using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). The primers used for mutagenesis are listed in *Supplementary file 1e*. Plasmids were produced in DH5α cells and purified using the PureLinkTM HiPure Plasmid Midiprep Kit (Thermo Scientific).

**qRT-PCR**

RNA was isolated using a NucleoSpin Extract II Isolation Kit (Macherey Nagel). The mRNA expression of selected genes was measured by qRT-PCR as described earlier (*Heming et al., 2018*). The primers used are listed in *Supplementary file 1f*. The relative expression level of each target gene was analysed using the 2−ΔΔCq method and was normalized to GAPDH.

**Chromatin immunoprecipitation**

For chromatin preparation, progenitor and differentiated ER-Hoxb8 cells were fixed using 1% formaldehyde for 5 min and reaction was stopped by adding 125 mM glycine. Chromatin was extracted as previously described (*Fujita and Fujii, 2013*). Approximately 1–5% of chromatin served as the input sample. DNA from input samples was isolated using phenol-chloroform extraction as described earlier (*Heming et al., 2018*). For immunoprecipitation, 3 µg antibody against Flag (Sigma-Aldrich), H3K27ac (Abcam), H3K27me3 (Cell Signaling Technology), normal Rabbit IgG (Cell Signaling,) or Mouse IgG1, κ Isotype control (BioLegend) was conjugated to 900 µg magnetic Dynabeads-Protein G (Thermo Scientific) at 4°C overnight. Sonicated chromatin was added to AB-conjugated Dynabeads and incubated at 4°C overnight. The Dynabeads were washed as described earlier (*Fujita and Fujii, 2013*). For elution, Dynabeads were incubated twice with elution buffer (0.05 M NaHCO3, 1% SDS) at 65°C for 15 min. DNA from eluates was isolated using phenol-chloroform extraction as with input samples. Values were taken into account only when the amount of DNA pulled down by using the antibody of interest was more than 5-fold increased over DNA pulled down by using IgG antibodies. The primers used for ChIP-PCR are listed in *Supplementary file 1g*.

**ATAC-seq**

Precursor and day 3 differentiated WT and C/EBPδ KO ER-Hoxb8 cells were harvested, washed, and cryopreserved in 50% FBS/40% growth media/10% DMSO using a freezing container at −80°C overnight. Cells were shipped to Active Motif to perform ATAC-seq as previously described (*Buenrostro et al., 2013*).

**Measurements of S100A8/A9 protein level**

The S100A8/A9 protein concentrations were measured using an in-house S100A8/A9 enzyme-linked immunosorbent assay (ELISA), as previously described (*Vogl et al., 2014*).

**Cytokine measurements by bead-based immunoassay**

IL-1α, IFN-γ, GM-CSF, MCP-1, IL-12p70, IL-1β, IL-10, IL-6, IL-27, IL-17A, IFN-β, and TNF-α were analysed using the bead-based immunoassay LEGENDplex mouse inflammation panel according to manufacturer’s instructions (BioLegend). Analytes were measured by flow cytometry using Navios (Beckmann Coulter).
Immunoblotting
Cells were lysed in M-PER Mammalian Protein Extraction Reagent (Thermo Scientific) containing a protease inhibitor mixture (Sigma-Aldrich). Protein concentration was determined, and equal amounts (15–30 µg) were run on an SDS-PAGE. After blotting on a nitrocellulose membrane, the membrane was incubated overnight with primary antibodies against: polyclonal rabbit S100A8 and S100A9 antibodies (originated from our own production; Vogl et al., 2014), GAPDH (Cell Signaling Technology), α/β-Tubulin (Cell Signaling Technology), and Flag (Sigma-Aldrich). Membranes were incubated with an HRP-linked secondary antibody (Agilent) for 1 hr. Chemiluminescence signal was detected using ChemiDoc XRS+ (Bio-Rad) together with ImageJ (National Institutes of Health) to quantify the signal intensity.

Phagocytosis
FluoSpheres polystrene microspheres (Thermo Scientific) that were shortly sonicated in a bath sonicator (Latex Beads) or pHrodo Red S. aureus Bioparticles Conjugate (S. aureus Bioparticles) were added to 5 x 10^5 differentiated cells at a ratio 1:10 for 2 hr at 37°C. The rate of phagocytosis was measured by flow cytometry using Navios (Beckmann Coulter).

Oxidative burst
Cells were stimulated using 10 nM PMA (Abcam) for 15 min or left untreated. After incubation, 15 µM DHR123 (Sigma-Aldrich) were added for another 15 min. The fluorescence signal was analysed using flow cytometry (Navios, Beckmann Coulter).

FACS analysis
BMCs and ER-Hoxb8 cells were differentiated using 40 ng/ml rmGM-CSF (ImmunoTools), harvested, stained for CD11b, Ly-6C, and appropriate Isotype control antibodies (all BioLegend) and measured using flow cytometry (Navios, Beckmann Coulter) to determine cell population purity and differentiation kinetics.

RNA-seq
Study population
For this study, we used bulk mRNA-sequencing (RNA-seq) data of PBMCs and monocytes from two subsets of participants in the German BioNRW Study (Witten et al., 2022). BioNRW actively recruits patients undergoing coronary angiography for the diagnosis and percutaneous coronary intervention of coronary artery disease, as well as age and gender matched healthy control individuals without history of cardiovascular disease, all aged 18–70 years of age. Patients receive standard cardiovascular care and medication (ACE-inhibitor, AT1-receptor blocker, β-blocker, diuretics, statin), according to current guidelines. Here, we included a total of 42 patients with sCAD or acute MI, as well as 39 of the corresponding age and sex matched controls.

The BioNRW Study is conducted in accordance with the guidelines of the Declaration of Helsinki. The research protocol, including the case report forms, was approved by the local ethics committee (#245-12). Written informed consent was obtained from all study participants.

Blood collection and isolation of PBMCs
In case of MI, blood samples were collected during the first 4 days following the event. EDTA blood was drawn from each subject by venipuncture. Sample processing followed within 2 hr. PBMCs were obtained from 40 ml blood by density gradient centrifugation (Ficoll; Biochrom). Lymphocytes were collected and washed twice with PBS. The pellet was re-suspended in freezing medium Cryo-SFM (PromoCell) and cryopreserved.

Isolation of monocyte subpopulations
After washing, PBMCs were stained with anti-human antibodies specific for CD2 (PE, RPA-2.10, T-cell marker), CD14 (APC, M5E2, monocyte subset differentiation), CD15 (PE, HIM1, granulocyte marker), CD16 (PE-Cy7, 3G8, monocyte subset differentiation), CD19 (PE, HIB19, B-cell marker), CD56 (PE, MY31, NK-cell marker), CD335 (PE, 9E2, NK-cell marker), HLA-DR (FITC, TU36, antigen-presenting
cells) (all from BD Biosciences), as reported by Cros et al., 2010. Cells were acquired on a FACS LSR II flow cytometer (BD Biosciences) and analysed using FlowJo software version 10 (Treestar Inc). For sorting of monocyte subsets, PBMCs were stained and sorted on a MoFlo Astrios cell sorter (Beckman Coulter). Cells were sorted in 1 ml of Isol-RNA lysis reagent (5-Prime GmbH) and frozen at −80°C. To avoid gender-specific effects, three representative male samples of each BioNRW diagnostic group (sCAD, MI, and control) were selected to be subjected to cell sorting and subsequent RNA isolation.

Differential expression analysis in PBMCs and monocytes

For mRNA profiling of PBMCs and monocyte subpopulations using RNA-seq, mRNA was enriched using the NEBNext Poly(A) Magnetic Isolation Module (NEB), followed by cDNA NGS library preparation (NEBNext Ultra RNA Library Prep Kit for Illumina, NEB). The size of the resulting libraries was controlled by the use of a Bioanalyzer High Sensitivity DNA Kit (Agilent Technologies) and quantified using the KAPA Library Quantification Kit for Illumina (Roche). Equimolar, appropriately pooled libraries were sequenced in a single read mode (75 cycles) on a NextSeq500 System (Illumina) using v2 chemistry, yielding in an average QScore distribution of 92%≥Q30 score. They were subsequently demultiplexed and converted to FASTQ files using bcl2fastq v2.20 Conversion software (Illumina). Data was quality controlled using FASTQC software and trimmed for adapter sequences using Trimomatic (Bolger et al., 2014).

General statistics

The statistical significance of the data was determined using Prism 5.0 software (GraphPad Software, San Diego, CA). Analyses between two groups were performed using an unpaired two-tailed Student’s t test. Comparisons among three or more groups were performed by using one-way ANOVA, followed by Bonferroni’s multiple means tests for comparing all pairs of columns. Differences were considered statistically significant at a probability (p-value) of <0.05.

Bioinformatics analysis

GeCKO-library screening

Analysis of counting the reads for each gRNA and differential analysis was performed using MaGeCK 0.5.9.3, a computational tool to identify important genes from GeCKO-based screens (Li et al., 2014). A modified RRA method with a redefined p value was used. Former RRA computed a significant p-value for genes in the middle of gRNA ranked list and thereby introducing false positives because the assumption of uniformity is not necessarily satisfied in real applications. Thus, top ranked % gRNAs were selected if their negative binomial p-values were smaller than a threshold, such as 0.05. If j of the n gRNAs targeting a gene were selected, then the modified value is defined as $p =\min (p_1, p_2, \ldots, p_j)$, where $j \leq n$. This modified RRA method could efficiently remove the effect of insignificant gRNAs in the assessment of gene significance. A permutation test where the gRNAs were randomly assigned to genes was performed to compute a p-value based on the $p$ values. By default, $100 \times n_g$ permutations are performed, where $n_g$ is the number of genes. We then compute the FDR from the empirical permutation p-values using the Benjamini-Hochberg procedure.

ATAC-seq

Sequence analysis was performed by mapping the paired-end 42 bp sequencing reads (PE42) generated by Illumina sequencing (using NextSeq500) to the genome using the BWA algorithm with default settings (‘bwa mem’). Only reads that passed Illumina’s purity filter, aligned with no more than two mismatches, and mapped uniquely to the genome were used in the subsequent analysis. In addition, duplicate reads (‘PCR duplicates’) were removed. BAM files provided by Active Motif were used to perform peak calling with MACS2, using paired-end mode with a bandwidth of 200 and q-value cutoff of 0.01. BedGraph files were converted to BigWig format for visualization with the Integrative Genomics Viewer (IGV) (Thorvaldsdóttir et al., 2013) using bedGraphToBigWig. Differential accessibility analyses for all possible comparisons between WT and/or C/EBPδ KO in day 0 and day 3 groups were carried out with GUAVA v1 (Divate and Cheung, 2018), which implements DESeq2 (Love et al., 2014). Differential peaks were defined as those merged intervals within a window of 5000 bp upstream and 3000 bp downstream of the transcription start site (TSS) showing an adjusted p-value (padj) <0.05 and log2 fold change ≥±1.5.
RNA-seq
The resulting reads were mapped to the human reference genome builds hg19 (monocytes) or hg38 (PBMCs) using Tophat2 (Kim et al., 2013) or HISAT2 v2.1.0 (Kim et al., 2019), counted by using the R package GenomicAlignments (Lawrence et al., 2013) or HTSeq v0.11.2 (Anders et al., 2015), and followed by differential expression analysis using DEseq2 (Love et al., 2014). The PBMCs dataset used for analysis consisted of 72 individuals, from which 36 were sCAD/MI cases and 36 were controls (21 females and 15 males in each group, mean age: 50.8±12.3 years), while the monocytes dataset contained read counts of classical, intermediate, and non-classical monocyte subpopulations from 9 male individuals (3 MI, 3 sCAD, and 3 controls). One sCAD non-classical monocyte sample had to be excluded from analysis due to low mapping rate; therefore, the monocytes dataset used for analysis contained 26 samples. Genes were considered differentially expressed at adjusted p<0.05 (Benjamini-Hochberg method). R was used to perform Pearson correlation tests and generate plots for the genes of interest from the normalized count data.

Conclusion
We found that the transcription factor C/EBPδ drives expression of the abundant alarmins S100A8 and S100A9, and demonstrated that C/EBPδ binding to specific sites on S100a8 and S100a9 promoter regions also induced changes in chromatin accessibility via JMJD3-mediated demethylation of H3K27me3 marks, which includes a so far unknown link. Due to the high relevance of S100A8/A9 alarmin expression in many inflammatory diseases, our findings may point to novel molecular targets for innovative anti-inflammatory therapeutic approaches.

Acknowledgements
The authors thank Ursula Nordhues, Eva Nattkemper, Heike Hater, Heike Berheide, Sina Mersmann, Elvira Barg, and Marianne Jansen-Rust for their excellent technical support, and Esta Sterneck (Center for Cancer Research, National Cancer Institute, Frederick, MD) for providing the C/EBPδ KO mice. This work was supported by grants from the Interdisciplinary Center of Clinical Research at the University of Münster (Ro2/023/19, Vo2/011/19), the German Research Foundation CRC 1009 B8, B9, and Z2, CRU 342 P3 and P5 and RO 1190/14-1 (to J Roth and T Vogl) and by the EU EFRE Bio NRW programme (005-1007-0006) to MS. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Additional information

| Funding                      | Grant reference number | Author      |
|------------------------------|------------------------|-------------|
| Deutsche Forschungsgemeinschaft | CRC 1009 B9            | Johannes Roth |
| Deutsche Forschungsgemeinschaft | CRC 1009 Z2            | Johannes Roth |
| Deutsche Forschungsgemeinschaft | CRC 1009 B8            | Thomas Vogl   |
| Deutsche Forschungsgemeinschaft | CRU 342 P3            | Johannes Roth |
| Deutsche Forschungsgemeinschaft | RO 1190/14-1          | Johannes Roth |
| Deutsche Forschungsgemeinschaft | CRU 342 P5            | Thomas Vogl   |
| Interdisciplinary Center of Clinical Research at the University of Münster | Ro2/023/19 | Johannes Roth |
Author contributions
Saskia-Larissa Jauch-Speer, Conceptualization, Formal analysis, Investigation, Writing - original draft, Writing - review and editing; Marisol Herrera-Rivero, Data curation, Software, Writing - review and editing; Nadine Ludwig, Investigation, Methodology; Bruna Caroline Véras De Carvalho, Jonas Wolf, Investigation; Leonie Martens, Data curation, Software; Achmet Imam Chasan, Methodology; Anika Witten, Supervision; Birgit Markus, Bernhard Schieffer, Resources; Thomas Vogl, Funding acquisition; Jan Rossaint, Conceptualization, Resources; Monika Stoll, Funding acquisition, Project administration, Resources, Supervision; Johannes Roth, Conceptualization, Funding acquisition, Project administration, Supervision, Writing - review and editing; Olesja Fehler, Conceptualization, Investigation, Project administration, Supervision, Writing - review and editing

Author ORCIDs
Saskia-Larissa Jauch-Speer http://orcid.org/0000-0002-6739-3051
Marisol Herrera-Rivero http://orcid.org/0000-0001-7064-9487
Achmet Imam Chasan http://orcid.org/0000-0001-5137-6890
Johannes Roth http://orcid.org/0000-0001-7035-8348
Olesja Fehler http://orcid.org/0000-0001-6386-7080

Ethics
Human subjects: The BioNRW Study is conducted in accordance with the guidelines of the Declaration of Helsinki. The research protocol, including the case report forms, was approved by the local ethics committee (#245-12). Written informed consent was obtained from all study participants. Mouse experiments were in accordance with German Animal Welfare Legislation and performed as approved by the North Rhine-Westphalia Office of Nature, Environment and Consumer Protection (LANUV) and the District Government and District Veterinary Office Muenster under the reference number 81-02.04.2019.A445.

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.75594.sa1
Author response https://doi.org/10.7554/eLife.75594.sa2

Additional files
Supplementary files
Supplementary file 1. List of oligonucleotides used for cloning, (qRT)PCR and mutagenesis. (a) List of guides (stated in 5’–3’ orientation) for cloning into lentCRISPR v2, related to Materials and methods. (b) List of primer (stated in 5’–3’ orientation) for amplifying GeCKO library and NGS, related to Materials and methods. (c) List of oligonucleotides (stated in 5’–3’ orientation, fw: forward, rv: reverse) for cloning steps to construct TRE_3xFlag-C/EBPδ vector, related to Materials and methods. (d) List of oligonucleotides (stated in 5’–3’ orientation, fw: forward, rv: reverse) for cloning steps to construct S100a8 and S100a9 reporter construct, related to Materials and methods. (e) List of oligonucleotides (stated in 5’–3’ orientation) for mutagenesis to disrupt specific sites within S100a8 and S100a9 reporter vectors, related to Materials and methods. (f) List of quantitative reverse transcription polymerase chain reaction (qRT-PCR) primer (in 5’–3’ orientation) used for qRT-PCR, related to Materials and methods. (g) List of chromatin immunoprecipitation (ChIP)-PCR primer (in 5’–3’ orientation) for S100a8 and S100a9 genomic locations, related to Materials and methods.
Transparent reporting form

Jauch-Speer et al. eLife 2022;11:e75594. DOI: https://doi.org/10.7554/eLife.75594
Data availability
GeCKO-screen data are deposited in ID PRJNA754262 at the NCBI's Database, RNA-seq data are deposited in ID 706411 at the NCBI SRA repository and ATAC-seq data are deposited in ID GSE200730 at the NCBI's GEO data repository.

The following datasets were generated:

| Author(s) | Year | Dataset title | Dataset URL | Database and Identifier |
|-----------|------|---------------|-------------|-------------------------|
| Jauch-Speer SL, Herrera-Rivero M, Ludwig N, Veras De Carvalho BC, Martens L, Wolf J, Imam Chasan A, Witten A, Markus B, Schieffer B, Vogl T, Rossaint J, Stoll M, Roth J, Fehler O | 2021 | GeCKO screen | https://www.ncbi.nlm.nih.gov/bioproject/PRJNA754262 | NCBI BioProject, PRJNA754262 |
| Witten A, Martens L, Schäfer A-C, Troidl C, Pankuweit S, Vlacil A-K, Oberoi R, Schieffer B, Grote K, Stoll M, Markus B | 2021 | monocyte subpopulation profiling | https://www.ncbi.nlm.nih.gov/bioproject/PRJNA706411 | NCBI BioProject, PRJNA706411 |
| Jauch-Speer SL, Herrera-Rivero M, Ludwig N, Veras De Carvalho BC, Martens L, Wolf J, Imam Chasan A, Witten A, Markus B, Schieffer B, Vogl T, Rossaint J, Stoll M, Roth J, Fehler O | 2022 | ATAC-seq in precursor and differentiated ER-Hoxb8 cells | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE200730 | NCBI Gene Expression Omnibus, GSE200730 |

References
Anders S, Pyl PT, Huber W. 2015. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics (Oxford, England) 31:166–169. DOI: https://doi.org/10.1093/bioinformatics/btu638, PMID: 25260700
Austermann J, Spiekermann C, Roth J. 2018. S100 proteins in rheumatic diseases. Nature Reviews. Rheumatology 14:528–541. DOI: https://doi.org/10.1038/s41584-018-0058-9, PMID: 30076385
Aydin S, Uğur K, Aydın S, Sahin İ, Yardım M. 2019. Biomarkers in acute myocardial infarction: current perspectives. Vascular Health and Risk Management 15:1–10. DOI: https://doi.org/10.2147/VHRM.S166157, PMID: 30697054
Balamurugan K, Sharan S, Klarmann KD, Zhang Y, Coppola V, Summers GH, Roger T, Morrison DK, Keller JR, Sterneck E. 2013. FBXW7α attenuates inflammatory signalling by downregulating C/EBPα and its target gene Tir. Nature Communications 4:1662. DOI: https://doi.org/10.1038/ncomms2677, PMID: 23575666
Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. 2013. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nature Methods 10:1213–1218. DOI: https://doi.org/10.1038/nmeth.2688, PMID: 24097267
Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, Kaufman PD. 2009. A versatile viral system for expression and depletion of proteins in mammalian cells. PLOS ONE 4:e6529. DOI: https://doi.org/10.1371/journal.pone.0006529, PMID: 19657394
Chakrabarty D, Zenker S, Rossaint J, Hölscher A, Pohlen M, Zarbock A, Roth J, Vogl T. 2017. Alarmin S100A8 Activates Alveolar Epithelial Cells in the Context of Acute Lung Injury in a TLR4-Dependent Manner. Frontiers in Immunology 8:1–16. DOI: https://doi.org/10.3389/fimmu.2017.01493, PMID: 29180999
Chang L-H, Huang H-S, Wu P-T, Jou I-M, Pan M-H, Chang W-C, Wang DDH, Wang J-M. 2012. Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice. PLOS ONE 7:e45378. DOI: https://doi.org/10.1371/journal.pone.0045378, PMID: 23028973
Chiou S-H, Winters IP, Wang J, Naranjo S, Dudgeon C, Tamburini FB, Brady JJ, Yang D, Grüner BM, Chuang C-H, Caswell DR, Zeng H, Chu P, Kim GE, Carpizo DR, Kim SK, Winslow MM. 2015. Pancreatic cancer modeling
using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes & Development 29:1576–1585. DOI: https://doi.org/10.1101/gad.264861.115, PMID: 26178787

Choi IY, Gerlag DM, Herenius MJ, Thrulings RM, Wijbrands CA, Foell D, Vogl T, Roth J, Tak PP, Holzinger D. 2015. MRPR8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 74:499–505. DOI: https://doi.org/10.1136/annrheumdis-2013-209323, PMID: 24297376

Cros J, Cagnard N, Woollard K, Patey N, Zhang S-Y, Senechal B, Puel A, Bitwas SK, Moshous D, Picard C, Jais J-P, D’Cruz D, Casanova J-L, Trouillet C, Geissmann F. 2010. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33:375–386. DOI: https://doi.org/10.1016/j.immuni.2010.08.012, PMID: 20832340

Cross SS, Hamdy FC, Deloulme JC, Rehman I. 2005. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46:256–269. DOI: https://doi.org/10.1111/j.1365-2559.2005.02097.x, PMID: 15720411

Das ND, Jung KH, Choi MR, Yoon HS, Kim SH, Chai YG. 2012. Gene networking and inflammatory pathway analysis in a JMJ3 knockdown human monocyte cell line. Cell Biochemistry and Function 30:224–232. DOI: https://doi.org/10.1002/cbf.1839, PMID: 22252741

Davis FM, denDekker A, Joshi AD, Wolf SJ, Audu C, Mangum K, Riordan MO, Kunkel SL, Cross SS, Hamdy FC, Deloulme JC, Rehman I. 2005. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46:256–269. DOI: https://doi.org/10.1111/j.1365-2559.2005.02097.x, PMID: 15720411

Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. 2009. The endogenous Toll-like receptor 4 agonist S100A8/A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. Journal of Leukocyte Biology 86:557–566. DOI: https://doi.org/10.1189/jlb.1008647, PMID: 19451397

Fassl SK, Aukermann J, Papantonopoulou O, Riemenschneider M, Sorg C, Roth J. 2004. Proinflammatory S100 proteins in arthritis and autoimmune disease. Journal of Autoimmunity 20:243–255. DOI: https://doi.org/10.1016/j.jaut.2016.07.011, PMID: 27528513

Fujita T, Burghard A, Ortkras T, Daber N, Imam Chasan A, Jauch S-L, Fehler O, Hillebrand J, Schakaki M, Freise N. 2019. S100A8/A9 as a therapeutic target in myocardial infarction: cellular mechanisms, transcriptome assessment reveals a dominant role for TLR4 in the activation of human monocytes by the alarmin MRP8. Journal of Immunology (Baltimore, Md) 194:575–583. DOI: https://doi.org/10.4049/jimmunol.1401085, PMID: 25505274

Gallagher KA. 2020. Palmitate-TLR4 signaling regulates the histone demethylase, JMJD3, in macrophages and impairs diabetic wound healing. European Heart Journal 41:2407–2423. DOI: https://doi.org/10.1093/eurheartj/ehz524, PMID: 31334753

Gallagher KA. 2020. Palmitate-TLR4 signaling regulates the histone demethylase, JMJD3, in macrophages and impairs diabetic wound healing. European Heart Journal 41:2407–2423. DOI: https://doi.org/10.1093/eurheartj/ehz524, PMID: 31334753

Heming M, Gran S, Jauch S-L, Fischer-Riepe L, Russo A, Klotz L, Hermann S, Schäfers M, Roth J, Barczyk-Kahliert K. 2018. Peroxisome Proliferator-Activated Receptor-γ Modulates the Response of
Macrophages to Lipopolysaccharide and Glucocorticoids. *Frontiers in Immunology* **9**:893. DOI: https://doi.org/10.3389/fimmu.2018.00893, PMID: 29867927

Hessian PA, Edgeworth J, Hogg N. 1993. MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. *Journal of Leukocyte Biology* **53**:197–204. PMID: 8445311.

Huang M, Wang Q, Long F, Di Y, Wang J, Zhun Z, Yu L. 2020. Jmjd3 regulates inflammasome activation and aggravates DSS-induced colitis in mice. *FASEB Journal* **34**:4017–4119. DOI: https://doi.org/10.1096/fj.201902200RR, PMID: 31971317

Jia W, Wu W, Yang D, Xiao C, Su Z, Huang Z, Li Z, Qin M, Huang M, Liu S, Long F, Mao J, Liu X, Zhu YZ. 2018. Histone demethylase JMJD3 regulates fibroblast-like synoviocyte-mediated proliferation and joint destruction in rheumatoid arthritis. *FASEB Journal* **32**:4031–4042. DOI: https://doi.org/10.1096/fj.201701483R, PMID: 29481307

Joung J, Konermann S, Gootenbergs JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F. 2017. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. *Nature Protocols* **12**:828–863. DOI: https://doi.org/10.1038/nprot.2017.016, PMID: 28339314

Kamar A, Fahed AC, Shibbani K, El-Hachem N, Bou-Slaiman S, Arabi M, Kurban M, Seidman JG, Seidman CE, Haidar R, Baydoun E, Nemrer G, Bitar F. 2017. A Novel Role for CCRP1 in A Lebanese Family with Congenital Cardiac Defects. *Frontiers in Genetics* **8**:1–13. DOI: https://doi.org/10.3389/fgen.2017.00217, PMID: 29326753

Kehl-Fie TE, Skaar EP. 2010. Nutritional immunity beyond iron: a role for manganese and zinc. *Current Opinion in Chemical Biology* **14**:218–224. DOI: https://doi.org/10.1016/j.cbpa.2010.03.008, PMID: 20015678

Kehl-Fie TE, Chitatay S, Hood MI, Damo S, Restrepo N, Garcia C, Munro KA, Chazin WJ, Skaar EP. 2011. Nutritional immunity beyond iron: a role for manganese and zinc. *Current Opinion in Chemical Biology* **15**:R36. DOI: https://doi.org/10.1016/j.cbpa.2011.07.004, PMID: 21843872

Kim D, Pertz EA, Trapnell C, Pimentel H, Kelley R, Salzberg SL. 2013. TopHat2: accurate alignment of transciptomes in the presence of insertions, deletions and gene fusions. *Genome Biology* **14**:R36. DOI: https://doi.org/10.1186/gb-2013-14-4-r36, PMID: 23618408

Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. 2019. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nature Biotechnology* **37**:907–915. DOI: https://doi.org/10.1038/s41587-019-0201-4, PMID: 31375807

Ko CY, Chang LH, Lee YC, Sternek E, Cheng CP, Chen SH, Huang AM, Tseng JT, Wang JM. 2012. CCAAT/ enhancer binding protein delta (CEBPD) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells. *Neurobiology of Aging* **33**:422. DOI: https://doi.org/10.1016/j.jneurobiolaging.2010.09.017, PMID: 21112127

Kruidenier L, Chung C, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, Eberhard D, Hutchinson S, Jones E, Katso R, Leveridge M, Mander PK, Mosley J, Ramirez-Molina C, Rowland P, Schofield CJ, et al. 2012. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. *Nature* **488**:404–408. DOI: https://doi.org/10.1038/nature11262, PMID: 22829401

Kummer MP, Vogl T, Ax T, Griepe A, Vieira-Saecker A, Jessen F, Gelpi E, Roth J, Heneka MT. 2012. Mpr14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing. The *Journal of Neuroscience* **32**:17824–17829. DOI: https://doi.org/10.1523/JNEUROSCI.1504-12.2012, PMID: 23223301

Kuruto-Niwa R, Nakamura M, Takeishi K, Nozawa R. 1998. Transcriptional regulation by C/EBP alpha and -beta in the expression of the gene for the MRP14 myeloid calcium binding protein. *Cell Structure and Function* **23**:109–118. DOI: https://doi.org/10.1016/S0196-4884(98)80085-1, PMID: 9706399

Kweon J, Kim Y. 2018. High-throughput genetic screens using CRISPR-Cas9 system. *Archives of Pharmacal Research* **41**:875–884. DOI: https://doi.org/10.1007/s12272-018-1029-z, PMID: 29637495

Lai PH, Wang W-L, Ko C-Y, Lee Y-C, Yang W-M, Shen T-W, Chang W-C, Wang J-M. 2008. HDAC1/HDAC3 modulates PPAR2 transgene through the sumoylated CEBPD in hepatic lipogenesis. *Biochimica et Biophysica Acta* **1783**:803–1814. DOI: https://doi.org/10.1016/j.bbamer.2008.06.008, PMID: 18619497

Lan F, Bayliss PE, Rinn JL, Whetstone JR, Wang JK, Chen S, Ivase S, Alpatov R, Isaeva I, Canaani E, Roberts TM, Chang HY, Shi Y. 2007. A histone H3 lysine 27 demethylase regulates animal posterior development. *Nature* **449**:689–694. DOI: https://doi.org/10.1038/nature06192, PMID: 17851529

Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C, Roth J. 2006. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. *Journal of Molecular Biology* **359**:961–972. DOI: https://doi.org/10.1016/j.jmb.2006.04.009, PMID: 16690079
Li R, Strohmeyer R, Liang Z, Lue L-F, Rogers J. 2004. CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer’s disease. Neurobiology of Aging 25:991–999. DOI: https://doi.org/10.1016/j.neurobiolaging.2003.10.016, PMID: 15212823

Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Iriarry RA, Liu JS, Brown M, Liu XS. 2014. MAGECK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biology 15:554. DOI: https://doi.org/10.1186/s13059-015-0554-4, PMID: 25476604

Li Y, Chen B, Yang X, Zhang C, Jiao Y, Li P, Liu Y, Li Z, Qiao B, Bond L, Wang W, Ma X-L, Du J. 2019. S100a8/a9 Signaling Causes Mitochondrial Dysfunction and Cardiomyocyte Death in Response to Ischemic/Reperfusion Injury. Circulation 140:751–764. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.039262, PMID: 31220942

Litvak V, Ramsey SA, Rust AG, Zak DE, Kennedy KA, Lampano AE, Nykter M, Shmulevich I, Aderem A. 2009. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nature Immunology 10:437–443. DOI: https://doi.org/10.1038/ni.1721, PMID: 19270711

Liu Y-W, Tseng H-P, Chen L-C, Chen B-K, Chang W-C. 2003. Functional cooperation of simian virus 40 promoter factor 1 and CCAAT/enhancer-binding protein beta and delta in lipopolysaccharide-induced gene activation of IL-10 in mouse macrophages. Journal of Immunology (Baltimore, Md) 171:821–828. DOI: https://doi.org/10.4049/jimmunol.171.2.821, PMID: 12847250

Liu Y-F, Wei J-Y, Shi M-H, Jiang H, Zhou J. 2016. Glucocorticoid Induces Hepatic Steatosis by Inhibiting Activating Transcription Factor 3 (ATF3)/S100A9 Protein Signaling in Granulocytic Myeloid-derived Suppressor Cells. The Journal of Biological Chemistry 291:21771–21785. DOI: https://doi.org/10.1074/jbc.M116.726364, PMID: 27573240

Loven E, Muhibehs MS, Tessier PA, Alexis NE, Duncan Hite R, Seeds MC, Peden DB, Meredith W. 2008. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respiratory Medicine 102:567–573. DOI: https://doi.org/10.1016/j.rmed.2007.11.011, PMID: 18164192

Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, Klenner L, Kuhn A, Foell D, Sorokin L, Lugter TA, Loser K, Langer E, Wei J-Y, Shi M-H, Jiang H, Zhou J. 2016. Glucocorticoid Induces Hepatic Steatosis by Inhibiting Activating Transcription Factor 3 (ATF3)/S100A9 Protein Signaling in Granulocytic Myeloid-derived Suppressor Cells. The Journal of Biological Chemistry 291:21771–21785. DOI: https://doi.org/10.1074/jbc.M116.726364, PMID: 27573240

Loven E, Muhibehs MS, Tessier PA, Alexis NE, Duncan Hite R, Seeds MC, Peden DB, Meredith W. 2008. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respiratory Medicine 102:567–573. DOI: https://doi.org/10.1016/j.rmed.2007.11.011, PMID: 18164192

Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, Klenner L, Kuhn A, Foell D, Sorokin L, Lugter TA, Rothe J, Beissert S. 2010. The Toll-like receptor 4 ligands MRP8 and MRP14 are crucial in the development of autoreactive CD8+ T cells. Nature Medicine 16:713–717. DOI: https://doi.org/10.1038/nm.2150, PMID: 20473308

Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15:550. DOI: https://doi.org/10.1186/s13059-014-0550-8, PMID: 25516281

Mayer TZ, Simard FA, Cloutier A, Vardhan H, Dubois CM, McDonald PP. 2013. The p38-MSK1 signaling cascade influences cytokine production through CREB and C/EBP factors in human neutrophils. Journal of Immunology (Baltimore, Md) 191:4299–4307. DOI: https://doi.org/10.4049/jimmunol.1301117, PMID: 24038085

Meugnier E, Coury F, Tebib J, Ferraro-Peyret C, Rome S, Bienvenu J, Vidal H, Sibilia J, Fabien N. 2011. Gene expression profiling in peripheral blood mononuclear cells of rheumatoid arthritis patients in response to anti-TNF-alpha treatments. Physiological Genomics 43:365–371. DOI: https://doi.org/10.1152/physiogenomics.00127.2010, PMID: 21266503

Monerieff H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, Roth J, Wedderburn LR. 2013. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford, England) 52:1467–1476. DOI: https://doi.org/10.1093/rheumatology/ket152, PMID: 23620557

Na J, Lee K, Na W, Shin J-Y, Lee M-J, Yune TY, Lee HK, Jung H-S, Kim WS, Ju B-G. 2016. Histone H3K27 Demethylase JMJD3 in Cooperation with NF-kB Regulates Keratinocyte Wound Healing. The Journal of Investigative Dermatology 136:847–858. DOI: https://doi.org/10.1016/j.jid.2015.11.029, PMID: 26802933

Na J, Shin JY, Jeong H, Lee JY, Kim BJ, Kim WS, Yune TY, Ju B-G. 2017. JMJD3 and NF-kB-dependent activation of Notch1 gene is required for keratinocyte migration during skin wound healing. Scientific Reports 7:1–12. DOI: https://doi.org/10.1038/s41598-017-06750-7, PMID: 28747631

Nahrendorf M, Swirski FK, Akawa E, Stangenberg L, Wurdinger T, Figueredo J-L, Libby P, Weissleder R, Pittet MJ. 2007. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. The Journal of Experimental Medicine 204:3037–3047. DOI: https://doi.org/10.1084/jem.20070885, PMID: 18025128

Nishioka K, Osahima S, Umeshita-Sasai M, Yamaguchi N, Mima T, Nomura S, Murata N, Shimizu M, Miyake T, Yoshizaki K, Suemura M, Kishimoto T, Sae K Y. 2000. Enhanced expression and DNA binding activity of two CCAAT/enhancer-binding protein isoforms, C/EBPbeta and C/EBPdelta, in rheumatoid synovium. Arthritis and Rheumatism 43:1591–1596. DOI: https://doi.org/10.1002/1529-0131(200007)43:7<1591::AID-ANR24>3.0.CO;2-9, PMID: 10920764

Sanjana NE, Shalem O, Zhang F. 2014. Improved versions and genome-wide libraries for CRISPR screening. Nature Methods 11:783–784. DOI: https://doi.org/10.1038/nmeth.3047, PMID: 25075903

Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (New York, N.Y.) 343:84–87. DOI: https://doi.org/10.1126/science.1247005, PMID: 24336571

Shepherd CE, Goyette J, Utter V, Rahimi F, Yang Z, Geczy CL, Halliday GM. 2006. Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiology of Aging 27:1554–1563. DOI: https://doi.org/10.1016/j.neurobiolaging.2005.09.033, PMID: 16253391

Sreejith G, Abdel-Latif A, Athanathan B, Annabathula R, Dhyani A, Noothi SK, Quai-Fe-Yan GA, Al-Sharea A, Pernes G, Dragoljevic D, Lal H, Schroder K, Hanaoka BY, Raman C, Grant MB, Hudson JE, Smyth SS, Porrello ER, Murphy AJ, Nagareddy PR. 2020. Neutrophil-Derived S100A8/A9 Amplify Granulopoiesis After

Jauch-Speier et al. eLife 2022;11:e75594. DOI: https://doi.org/10.7554/eLife.75594
Myocardial Infarction. *Circulation* **141**:1080–1094. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.043833, PMID: 31941367

Sternbeck E, Paylor R, Jackson-Lewis V, Libbey M, Przedborski S, Tessarollo L, Crawley JN, Johnson PF. 1998. Selectively enhanced contextual fear conditioning in mice lacking the transcriptional regulator CCAAT/enhancer binding protein delta. *PNAS* **95**:10908–10913. DOI: https://doi.org/10.1073/pnas.95.18.10908, PMID: 9724803

Thorvaldsdóttir H, Robinson JT, Mesirov JP. 2013. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Briefings in Bioinformatics* **14**:178–192. DOI: https://doi.org/10.1093/bib/bbs017, PMID: 22517427

van Lent PLEM, Grevers L, Blom AB, Słojeťas A, Mörts JS, Vogl T, Nacken W, van den Berg WB, Roth J. 2008. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. *Annals of the Rheumatic Diseases* **67**:1750–1758. DOI: https://doi.org/10.1136/ard.2007.077800, PMID: 18055478

van Lent PLEM, Blom AB, Schelbergen RFP, Słojeťas A, Lafefer FPJG, Lemsw WF, Cats H, Vogl T, Roth J, van den Berg WB. 2012. Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. *Arthritis and Rheumatism* **64**:1466–1476. DOI: https://doi.org/10.1002/art.34315, PMID: 22143922

Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehhardt C, van Zoelen MAD, Nacken W, Foei D, van der Poll T, Sorg C, Roth J. 2007. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. *Nature Medicine* **13**:1042–1049. DOI: https://doi.org/10.1038/nm1638, PMID: 17767165

Vogl T, Eisenblätter M, Völler T, Zenker S, Hermann S, van Lent P, Faust A, Geyer C, Petersen B, Roebrock K, Schäfers M, Bremer C, Roth J. 2014. Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity. *Nature Communications* **5**:1–12. DOI: https://doi.org/10.1038/ncomms5593, PMID: 25098555

Vogl T, Stratiss A, Wixler V, Völler T, Thuainayagam S, Jorch SK, Zenker S, Dreiling A, Challen GA, Vakoc CR. 2017. Conservation and innovation in the DUX4-family gene network. *Briefings in Bioinformatics* **23**:5589. DOI: https://doi.org/10.1093/nar/gkj422, PMID: 16397300

Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. 2000. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. *The Journal of Biological Chemistry* **275**:6259–6266. DOI: https://doi.org/10.1074/jbc.275.9.6259, PMID: 10692422

Wang GG, Calvo KR, Pasillas MP, Sykes DB, Häcker H, Kamps MP. 2006a. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. *Nature Methods* **23**:54–66. DOI: https://doi.org/10.1038/s41598-022-08600-7, PMID: 35379829

Wang GG, Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. 2000. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. *The Journal of Biological Chemistry* **275**:6259–6266. DOI: https://doi.org/10.1074/jbc.275.9.6259, PMID: 10692422

Wang JM, Ko CY, Chen LC, Wang WL, Chang WC. 2006b. Functional role of NF-IL6beta and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene. *Nucleic Acids Research* **34**:217–231. DOI: https://doi.org/10.1093/nar/gkj422, PMID: 16397300

Wang Q, Ozer HG, Wang B, Zhang M, Urabe G, Huang Y, Kent KC, Guo L-W. 2021. A hierarchical and subpopulation-specific miRNA expression sets in acute and stable coronary artery disease. *Methods & Clinical Development* **12**:15523–15537. DOI: https://doi.org/10.1016/j.ajpath.2012.10.013, PMID: 23177475

Whiddon JL, Ozer HG, Wang B, Zhang M, Urabe G, Huang Y, Kent KC, Guo L-W. 2021. A hierarchical and subpopulation-specific miRNA expression sets in acute and stable coronary artery disease. *Methods & Clinical Development* **12**:15523–15537. DOI: https://doi.org/10.1016/j.ajpath.2012.10.013, PMID: 23177475

Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. 2007. JMJD3 is a histone H3K27 demethylase. *Cell Research* **17**:5589. DOI: https://doi.org/10.1038/cr.2007.83, PMID: 17923864

Yan C, Johnson PF, Tang H, Ye Y, Wu M, Gao H. 2013. CCAAT/enhancer-binding protein δ is a critical mediator of lipopolysaccharide-induced acute lung injury. *The American Journal of Pathology* **182**:420–430. DOI: https://doi.org/10.1016/j.ajpath.2012.10.013, PMID: 23177475

Yang Q, Li X, Chen H, Cao Y, Xiao Q, He Y, Wei J, Zhou J. 2017. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transcription repression in cancer. *Oncogene* **36**:2969–2980. DOI: https://doi.org/10.1038/onc.2016.448, PMID: 28092673

Yan C, Johnson PF, Tang H, Ye Y, Wu M, Gao H. 2013. CCAAT/enhancer-binding protein δ is a critical mediator of lipopolysaccharide-induced acute lung injury. *The American Journal of Pathology* **182**:420–430. DOI: https://doi.org/10.1016/j.ajpath.2012.10.013, PMID: 23177475

Yan C, Johnson PF, Tang H, Ye Y, Wu M, Gao H. 2013. CCAAT/enhancer-binding protein δ is a critical mediator of lipopolysaccharide-induced acute lung injury. *The American Journal of Pathology* **182**:420–430. DOI: https://doi.org/10.1016/j.ajpath.2012.10.013, PMID: 23177475
Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, Kenner L, Tschachler E, Wagner EF. 2008. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Research & Therapy 10:201. DOI: https://doi.org/10.1186/ar2338, PMID: 18226189
## Appendix 1—key resources table

| Reagent type (species or resource) | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| gene (Mus musculus)              | S100a8      | NCBI                | Gene ID:20201 |                        |
| gene (Mus musculus)              | S100a9      | NCBI                | Gene ID:20202 |                        |
| Strain, strain background (Escherichia coli) | Subcloning Efficiency DH5α Competent Cells | Thermo Fisher Scientific | Cat# 18265017 |                        |
| Strain, strain background (Staphylococcus aureus) | pHrodo Red S. aureus Bioparticles Conjugate | Thermo Fisher Scientific | Cat# A10010 | 5 × 10⁶ per 0.5 × 10⁶ cells |
| Genetic reagent (Mus musculus)   | Cebpδtm1Pfj/Cebpδtm1Pfj | PMID:9724803 | RRID: MGI:3606309 | Esta Sterneck (CCR, NIH, MD) |
| Genetic reagent (Mus musculus)   | B6.J 129Gli.1gsc2tm1(TgCAG-Cas9*) | Jackson Laboratory | Stock# 028239 RRID:IMSR_JAX:028239 | PMID:26178787 |
| Cell line (Mus musculus)         | WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Cell line (Mus musculus)         | Cas9-expressing ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Cell line (Mus musculus)         | C/EBPδ KO ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Cell line (Homo sapiens)         | HEK293T     | ATCC                | RRID:CVCL_0063 |                        |
| Transfected construct (synthetic) | Cas9+PHF8 gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | Cas9+CSR1P1 gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | Cas9+HAND1 gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | Cas9+FBXW7 gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | Cas9+ATF3 gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | Cas9+STAT3 gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | Cas9+KL55 gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | Cas9+IRF7 gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | Cas9+C/EBPδ gRNA in WT ER-Hoxb8 cells | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a8 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a8 s1 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a8 s2 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a8 s3 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a8 s2+3 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a9 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a9 s1 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a9 s2 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a9 s3 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | MSCV S100a9 s2+3 prom_GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Transfected construct (synthetic) | MSCV S100a9-p4 prom-GFP in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | TRE_3xFlag-C/EBPß in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Transfected construct (synthetic) | TRE_ctrl in HEK293T | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Biological sample (Homo sapiens)  | Patient-derived PBMCs | PMID: 35379829 | N/A | BioNRW Study |
| Antibody                         | Anti-mouse S100A8 (rabbit polyclonal) | PMID: 25098555 | N/A | ELISA (1:460) WB (1:1500) |
| Antibody                         | Anti-mouse S100A9 (rabbit polyclonal) | PMID: 25098555 | N/A | ELISA (1:2300) WB (1:1000) |
| Antibody                         | Anti-mouse S100A9-RTIC (rabbit polyclonal) | This paper | N/A | FACS (5 µg/ml) |
| Antibody                         | Anti-mouse Ly-6B.2 Allot antigen (7/4) (rat monoclonal) | BioRad | Cat# MCA771F, RRID: AB_322951 | Flow cytometry (1:200) |
| Antibody                         | Anti-mouse Gr-1 (RB6-8C5) from hybridoma cells (recombinant monoclonal) | This paper | N/A | Flow cytometry (1:200) AG Zarbock (Department of Anesthesiology, UKM) |
| Antibody                         | Anti-mouse CD11b-Pb (M1/70) (rat monoclonal) | BioLegend | Cat# 101224, RRID: AB_755986 | FACS (1:100) Flow cytometry (1:200) |
| Antibody                         | Anti-mouse Ly-6C-PE (HK1.4) (rat monoclonal) | BioLegend | Cat# 128008, RRID: AB_1186132 | FACS (1:100) Flow cytometry (1:200) |
| Antibody                         | Anti-IgG2b, κ Isotype control-Pb (RTK4330) (rat monoclonal) | BioLegend | Cat# 400627, RRID: AB_493561 | Flow cytometry (1:200) |
| Antibody                         | Anti-IgG2c, κ Isotype control-PE (RTK4174) (rat monoclonal) | BioLegend | Cat# 400707, RRID: AB_326573 | Flow cytometry (1:200) |
| Antibody                         | Anti-GAPDH (14 C10) (rabbit monoclonal) | Cell Signaling Technology | Cat# 2118, RRID: AB_561053 | WB (1:1000) |
| Antibody                         | Anti-alpha/beta-Tubulin (rabbit polyclonal) | Cell Signaling Technology | Cat# 2148, RRID: AB_2288042 | WB (1:1000) |
| Antibody                         | Anti-H3K27me3 (C36B11) (rabbit monoclonal) | Cell Signaling Technology | Cat# 9733, RRID: AB_2616029 | ChIP(3 µg) |
| Antibody                         | Normal IgG control (rabbit polyclonal) | Cell Signaling Technology | Cat# 2729, RRID: AB_1031062 | ChIP(3 µg) |
| Antibody                         | Anti-H3K27ac (rabbit polyclonal) | Abcam | Cat# ab4729, RRID: AB_2118291 | ChIP(3 µg) |
| Antibody                         | Anti-FLAG M2 (mouse monoclonal) | Sigma-Aldrich | Cat# F1804, RRID: AB_2620044 | ChIP(3 µg) WB (1:1500) |
| Antibody                         | IgG1 Isotype control (MOPC-21) (mouse monoclonal) | BD Biosciences | Cat# 55421, RRID: AB_395252 | ChIP(3 µg) |
| Antibody                         | Anti-Rabbit Immunoglobulins/HRP (goat polyclonal) | Agilent | Cat# P0448, RRID: AB_2617138 | WB (1:4000) |
| Antibody                         | Anti-Mouse Immunoglobulins/HRP (rabbit polyclonal) | Agilent | Cat# P0260, RRID: AB_2436929 | WB (1:2000) |
| Antibody                         | Anti-CD2-PE (RR-2-10) (mouse monoclonal) | BD Biosciences | Cat# 555327, RRID: AB_395734 | FACS (1:20) |
| Antibody                         | Anti-CD14-APC (MSE2) (mouse monoclonal) | BD Biosciences | Cat# 555399, RRID: AB_395856 | FACS (1:20) |
| Antibody                         | Anti-CD15-PE (H98) (mouse monoclonal) | BD Biosciences | Cat# 555402, RRID: AB_395802 | FACS (1:5) |
| Antibody                         | Anti-CD19 PE (H619) (mouse monoclonal) | BD Biosciences | Cat# 555413, RRID: AB_395813 | FACS (1:20) |
| Antibody                         | Anti-CD16-PE-Cy7 (3 G8) (mouse monoclonal) | BD Biosciences | Cat# 55744, RRID: AB_396850 | FACS (1:20) |
### Appendix 1 Continued

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Antibody                          | Anti-CD56-PE (MY31) (mouse monoclonal) | BD Biosciences | Cat# 556647, RRID: AB_396511 | FACS (1:5) |
| Antibody                          | Anti-CD335-PE (9E2/NKp46) (mouse monoclonal) | BD Biosciences | Cat# 557991, RRID: AB_396974 | FACS (1:20) |
| Antibody                          | Anti-HLA-DR-FITC (TU3a) (mouse monoclonal) | BD Biosciences | Cat# 555560, RRID: AB_395942 | FACS (1:5) |
| Recombinant DNA reagent           | pCW57.1 mDux-CA | PMID:28459454 | RRID: Addgene_99284 | All-in-one lentisvector with tet-inducible mouse Dux |
| Recombinant DNA reagent           | pcDNA 3.1(+) mouse C/EBP delta | Johnson Laboratory | RRID: Addgene_12559 | Mouse C/EBPδ cDNA |
| Recombinant DNA reagent           | TRE_3xFlag-C/EBPδ6 | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | TRE_ctrl | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentGuide-puro for GeCKO screen | PMID:25075903 | RRID: Addgene_1000000053 | Lentiviral pooled libraries for genome-wide CRISPR/Cas9 Knock-outs |
| Recombinant DNA reagent           | lentCRISPrv2 | PMID:25075903 | RRID: Addgene_52961 | Lentisvector with CRISPR/Cas9 expression |
| Recombinant DNA reagent           | lentCRISPrv2.PHF8 gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentCRISPrv2.CSRP1 gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentCRISPrv2-HAND1 gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentCRISPrv2.FBXW7 gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentCRISPrv2-ATF3 gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentCRISPrv2-STAT3 gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentCRISPrv2.KLF5 gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentCRISPrv2.IRF7 gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | lentCRISPrv2.C/EBPβ gRNA | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | pLent: CMV GFP Blast (659-1) | PMID:19657394 | RRID: Addgene_17445 | Lentiviral eGFP expression vector |
| Recombinant DNA reagent           | MSCV-PIG-empty | PMID:29316427 | RRID: Addgene_105594 | Empty control vector with GFP marker and puro resistance |
| Recombinant DNA reagent           | MSCV S100a8 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | MSCV S100a8 s1 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | MSCV S100a8 s2 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | MSCV S100a8 s3 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | MSCV S100a8 s2+3 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | MSCV S100a9 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent           | MSCV S100a9 s1 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |

Appendix 1 Continued on next page
### Appendix 1 Continued

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Recombinant DNA reagent | MSCV S100a9 s2 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent | MSCV S100a9 s3 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent | MSCV S100a9 s4 prom_GFP | This paper | N/A | AG Roth (Institute of Immunology, WWU Münster) |
| Recombinant DNA reagent | psPAX2 | Trono Laboratory | RRID: Addgene_12260 | Lentiviral packaging plasmid |
| Recombinant DNA reagent | pCMV-VSV-G | Weinberg Laboratory | RRID: Addgene_8454 | Envelope protein for producing lentiviral particles |
| Sequence-based reagent | Cloning primers | This paper | Listed in Supplementary file 1a, c, d |
| Sequence-based reagent | GeCKO library amplification and NGS primers | This paper | Listed in Supplementary file 1b |
| Sequence-based reagent | Mutagenesis primers | This paper | Listed in Supplementary file 1e |
| Sequence-based reagent | qPCR primers | This paper | Listed in Supplementary file 1f, g |
| Peptide, recombinant protein | rm mouse GM-CSF | ImmunoTools | Cat# 12343137 | 40 ng/ml in vitro |
| Peptide, recombinant protein | LPS from Salmonella enteritidis | Sigma-Aldrich | Cat# L6011 | 0.5 mg/ml in vivo |
| Peptide, recombinant protein | LPS from Escherichia coli O55:B5 | Sigma-Aldrich | Cat# L2880 | 10 ng/ml in vitro |
| Peptide, recombinant protein | rm mouse IL-4 | Peprotech | Cat# 214-14 | 20 ng/ml in vitro |
| Peptide, recombinant protein | rm mouse IFN-γ | ImmunoTools | Cat# 12343536 | 50 ng/ml in vitro |
| Commercial assay or kit | Nucleospin RNA, Mini kit for RNA purification | Macherey Nagel | Cat# 740955.50 |
| Commercial assay or kit | QuikChange II XL Site-Directed Mutagenesis Kit | Agilent Technologies | Cat# 200521 |
| Commercial assay or kit | PureLink HiPure Plasmid Miniprep Kit | Thermo Fisher Scientific | Cat# K210002 |
| Commercial assay or kit | NEBNext High-Fidelity 2× PCR Master Mix | NEB | Cat# M0541S |
| Commercial assay or kit | QIAquick PCR Purification Kit | Qiagen | Cat# 28104 |
| Commercial assay or kit | Bioanalyzer High Sensitivity DNA Analysis Agilent High Sensitivity DNA Kit | Agilent | Cat# 5067-4626 |
| Commercial assay or kit | 20% PhiX spike in (Illumina PhiX control kit) | Illumina | Cat# FC-110-3001 |
| Commercial assay or kit | NextSeq 500/550 High Output Kit v2.5 (75 Cycles) | Illumina | Cat# 20024906 |
| Commercial assay or kit | NEBNext Ultra RNA Library Prep Kit for Illumina | NEB | Cat# E7530 |
| Commercial assay or kit | LEGENDplex Mouse Inflammation Panel (13-plex) | BioLegend | Cat# 740446 |
| Chemical compound, drug | Doxycycline | Sigma-Aldrich | Cat# D9891 | 2 µg/ml |
| Chemical compound, drug | Puromycin | InvivoGen | Cat# ant-pr-1 | 3–20 µg/ml |
| Chemical compound, drug | GSK-J4 HCl | SelleckChem | Cat# S7070 | 5 µM |
| Chemical compound, drug | β-Estradiol | Sigma-Aldrich | Cat# E8875 | 1 µM |

Appendix 1 Continued on next page
### Appendix 1 Continued

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Chemical compound, drug | Polybrene | Sigma-Aldrich | Cat# 107689 | 8 µg/ml |
| Chemical compound, drug | Protease Inhibitor Cocktail | Sigma-Aldrich | Cat# P8340 | 1:1000 |
| Chemical compound, drug | Dynabead Protein G for Immunoprecipitation | Thermo Fisher Scientific | Cat# 10004D | ChIP (1:10) |
| Chemical compound, drug | M-PER Mammalian Protein Extraction Reagent | Thermo Fisher Scientific | Cat# 78501 | 1× |
| Chemical compound, drug | Dihydrorhodamine 123 | Sigma-Aldrich | Cat# D1054 | 15 µm |
| Chemical compound, drug | NEBNext Poly(A) mRNA Magnetic Isolation Module | NEB | Cat# E7490 | |
| Chemical compound, drug | DNA Polymerase I, Large (Klenow) Fragment | NEB | Cat# M0210 | |
| Chemical compound, drug | FluoSpheres Polystyrene Microspheres, 1.0 µm, blue-green fluorescent (430/465) | Thermo Fisher Scientific | Cat# F13080 | 5 × 10^6 per 0.5 × 10^6 cells |
| Software, algorithm | AliBaba2.1 | PMID:11808873 | | http://gene-regulation.com/pub/programs/alibaba2/ |
| Software, algorithm | FlowJo Software | BD Biosciences | | https://www.flowjo.com/solutions/flowjo/ |
| Software, algorithm | MaGeCK 0.5.9.3 | PMID:25476604 | | https://sourceforge.net/p/mageck/wiki/Home/ |